



US006638518B1

(12) **United States Patent**
Ratliff et al.

(10) **Patent No.:** US **6,638,518 B1**
(45) **Date of Patent:** **Oct. 28, 2003**

- (54) **METHOD FOR INHIBITING INFLAMMATORY RESPONSES**
- (75) Inventors: **Timothy L. Ratliff**, Iowa City, IA (US);
Joel N. Kline, Iowa City, IA (US)
- (73) Assignee: **University of Iowa Research Foundation**, Iowa City, IA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: **09/510,031**
- (22) Filed: **Feb. 22, 2000**

Related U.S. Application Data

- (60) Provisional application No. 60/121,177, filed on Feb. 22, 1999.
- (51) **Int. Cl.**⁷ **A61K 45/00**; A61K 39/00
- (52) **U.S. Cl.** **424/282.1**; 424/190.1;
424/192.1
- (58) **Field of Search** 424/184.1, 185.1,
424/190.1, 234.1, 248.1, 278.1, 282.1, 192.1;
530/300, 350

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 4,716,038 A * 12/1987 Stanford et al.
4,938,949 A 7/1990 Borch et al.
5,618,916 A 4/1997 Ratliff et al.
5,811,399 A * 9/1998 Khavinson et al.
6,245,883 B1 * 6/2001 Heerze et al.

FOREIGN PATENT DOCUMENTS

- EP 0322990 7/1989 C07K/7/06
WO 95/25744 * 9/1995
WO 97/23624 7/1997 C12N/15/31
WO 99/37319 * 7/1999

OTHER PUBLICATIONS

- Kumar et al., "Murine model of chronic human asthma," *Immunology and Cell Biology*. 2001;79:141-144.
- Lee et al., "Administration of interleukin-12 exerts a therapeutic instead of a long-term preventive effect on mite *Der p I* allergen-induced animal model of airway inflammation," *Immunology*. 1999;97:232-240.
- Leong et al., "Understanding the pathogenesis of allergic asthma using mouse models," *Annals of Allergy, Asthma, & Immunology*. 2001;87:96-109.
- Umland et al., "Effects of cyclosporin A and dinactin on T-cell proliferation, interleukin-5 production, and murine pulmonary inflammation," *Am. J. Respir. Cell Mol. Biol.* 1999;20:481-492.
- Abou-Zeid et al., "Characterization of Fibronectin-Binding Antigens Released by *Mycobacterium tuberculosis* and *Mycobacterium bovis* BCG," *Infect. Immun.*, 56(12):3046-3051 (1988).
- Aslanzadeh et al., "Characterization of Soluble Fibronectin Binding to Bacille Calmette-Guérin," *J. Gen. Microbiol.*, 135:2735-2741 (1989).

- Ausubel, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., United States, Title page, publication page, and table of contents only, 12 pages (1994).
- Beasley et al., "Cellular Events in the Bronchi in Mild Asthma and after Bronchial Provocation," *Am. Rev. Respir. Dis.*, 139(3):806-817 (1989).
- Bliss et al., "IL-12, as an Adjuvant, Promotes a T Helper 1 Cell, but Does Not Suppress a T Helper 2 Cell Recall Response," *J. Immunol.*, 156(3):887-894 (1996).
- Brosius et al., "Gene Organization and Primary Structure of a Ribosomal RNA Operon from *Escherichia coli*," *J. Mol. Biol.*, 148(2):107-127 (1981).
- Bruijnzeel, "Eosinophil Tissue Mobilization in Allergic Disorders," *Cells and Cytokines in Lung Inflammation. Ann. NY Acad. Sci.*, 725:259-267 (1994).
- Clutterbuck et al., "Human Interleukin 5 (IL-5) Regulates the Production of Eosinophils in Human Bone Marrow Cultures: Comparison and Interaction With IL-1. IL-3. IL-6 and GM-CSF." *Blood*, 73(6):1504-1512 (1989).
- Corrigan et al., "CD4 T-Lymphocyte Activation in Asthma is Accompanied by Increased Serum Concentrations of Interleukin 5 Effect of Glucocorticoid Therapy," *Ann. Rev. Respir. Dis.*, 147(3):540-547 (1993).
- Del Prete et al., "Purified Protein Derivative of *Mycobacterium tuberculosis* and Excretory-Secretory Antigen(s) of *Toxocara canis* Expand in Vitro Human T Cells with Stable and Opposite (Type 1 T Helper or Type 2 T Helper) Profile of Cytokine Production," *J. Clin. Invest.*, 88, 346-350 (1991).
- Erb et al., "Infection of Mice with *Mycobacterium bovis*-Bacillus Calmette-Guérin (BCG) Suppresses Allergen-induced Airway Eosinophilia," *J. Exp. Med.*, 187(4):561-569 (1998).
- Evans et al., National Trends in the Morbidity and Mortality of Asthma in the U.S.; Prevalence, Hospitalization, and Death from Asthma Over Two Decades: 1965-184, *Chest*, 91(6):65S-74S (1987).
- Field et al., "Evidence for Excessive Th2 CD4+ Subset Activity in Vivo," *J. Immunol.*, 151(1):48-59 (1993).
- Gajewski et al., "Anti-Proliferative Effect of IFN-γ in Immune Regulation. I. IFN-γ Inhibits the Proliferation of Th2 but Not Th1 Murine Helper T Lymphocyte Clones," *J. Immunol.*, 140(12):4245-4252 (1988).

(List continued on next page.)

Primary Examiner—Patricia A. Duffy
(74) *Attorney, Agent, or Firm*—Mueiting, Raasch & Gebhardt, P.A.

(57) **ABSTRACT**

The present invention provides methods for treating at least one symptom of an inflammatory response in a mammal by administering a polypeptide to the mammal. The polypeptide can be a microbial polypeptide, or a Mycobacterial polypeptide. The present invention further provides an inflammation reaction inhibiting composition that includes a microbial polypeptide and a pharmaceutically acceptable carrier.

12 Claims, 11 Drawing Sheets

OTHER PUBLICATIONS

- Grünig et al., "Requirement for IL-132 Independently of IL-4 in Experimental Asthma," *Science*, 282(5397):2261-2263 (1998).
- Hirai et al., "Enhancement of Human Basophil Histamine Release by Interleukin 5," *J. Exp. Med.*, 172(4):1525-1528 (1990).
- Hunter et al., "Isolation and characterization of the highly immunogenic cell wall-associated protein of *Mycobacterium leprae*," *J. Immunol.*, 142(8):2864-2872 (1989).
- Jeffery et al., "Bronchial Biopsies in Asthma, An Ultrastructural Quantitative Study and Correlation with Hyperreactivity," *Am. Rev. Respir. Dis.*, 140:1745-1753 (1989).
- Kavoussi et al., "Fibronectin-mediated Calmette-Guerin Bacillus Attachment to Murine Bladder Mucosa Requirement for the Expression of an Antitumor Response." *J. Clin. Invest.*, 85:62-67 (1990).
- Kim et al., "Ribonuclease S-peptide as a carrier in fusion proteins," *Protein Sci.*, 2(2):348-356 (1993).
- Kline et al., "*Mycobacterium bovis* BCG fibronectin attachment protein (FAP-B) prevents the development of airway eosinophilia and bronchial hyperreactivity in a murine model of asthma," Abstract and Poster, Ann. Meeting, Am. Thoracic Society, Apr., 1999, *Am. J. Respir. Crit. Care Med.*, 159, 21 pages (Apr., 1999).
- Laitinen et al., "Damage of the Airway Epithelium and Bronchial Reactivity in Patients with Asthma," *Am. Rev. Respir. Dis.*, 131:599-606 (1985).
- Laqueyrie et al., "Cloning, Sequencing, and Expression of the *apa* Gene Coding for the *Mycobacterium tuberculosis* 45/47-Kilodalton Secreted Antigen Complex," *Infect. Immun.*, 63(10):4003-4010 (1995).
- Lopez et al., "Recombinant human interleukin 5 is a selective activator of human eosinophil function," *J. Exp. Med.*, 167:219-223 (1988).
- Marini et al., "Cytokine mRNA Profile and Cell Activation in Bronchoalveolar Lavage Fluid from Nonatopic Patients with Symptomatic Asthma," *Chest*, 102(3):661-669 (1992).
- Metzger et al., "Late Asthmatic Responses: Inquiry into Mechanisms and Significance," *Clin. Rev. All.*, 3(2):145-165 (1985).
- Metzger et al., "Bronchoalveolar Lavage of Allergic Asthmatic Patients following Allergen Bronchoprovocation," *Chest*, 89(4):477-483 (1986).
- Metzger et al., "Local Allergen Challenge and Bronchoalveolar Lavage of Allergic Asthmatic Lungs: Description of the Model and Local Airway Inflammation," *Am. Rev. Respir. Dis.*, 135(2):433-440 (1987).
- Micallef et al., "Interferon- γ -inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon- γ production," *Eur. J. Immunol.*, 26:1647-1651 (1996).
- Moore et al., "Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRF1," *Science*, 248(4960):1230-1234 (1990).
- Mosmann et al., "Two Types of Murine Helper T Cell Clone I. Definition According to Profiles of Lymphokine Activities and Secreted Proteins," *J. Immunol.*, 136(7):2348-2357 (1986).
- National Asthma Education and Prevention Program, *Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma*, National Institutes of Health, Bethesda, Md., 153 pages (1997).
- O'Connor et al., "The Role of Allergy and Nonspecific Airway Hyperresponsiveness in the Pathogenesis of Chronic Obstructive Pulmonary Disease," *Am. Rev. Respir. Dis.*, 140(1):225-252 (1989).
- Parronchi et al., "Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production," *Proc. Natl. Acad. Sci. USA*, 88(10):4538-4542 (1991).
- Parronchi et al., "IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones" *J. Immunol.*, 149(9):2977-2983 (1992).
- Ratliff et al., "Attachment of Mycobacteria to Fibronectin-coated Surfaces," *J. Gen. Microbiol.*, 134(5):1307-1313 (1988).
- Ratliff et al., "Purification of a Mycobacterial Adhesin for Fibronectin," *Infect. Immun.*, 61(5):1889-1894 (1993).
- Robbins et al., *Pathologic Basis of Disease second edition*, W. B. Saunders Co., Philadelphia, Title page, publication page, and pages 689-692 (1979).
- Robinson et al., "Predominant T_{H2}-like bronchoalveolar T-lymphocyte population in atopic asthma," *N. Engl. J. Med.*, 326(5):298-304 (1992).
- Robinson et al., "Activation of CD4⁺ T cells, increased T_{H2}-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma," *J. All. Clin. Immunol.*, 92(2):313-324 (1993).
- Robinson et al., "Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma," *J. All. Clin. Immunol.*, 92(3):397-403 (1993).
- Romagnani, "Human T_{H1} and T_{H2} subsets: doubt no more," *Immunol. Today*, 12(8):256-257 (1991).
- Romain et al., "Identification of a *Mycobacterium bovis* BCG 45/47-Kilodalton Antigen Complex, an Immunodominant Target for Antibody Response after Immunization with Living Bacteria," *Infect. Immun.*, 61(2):742-750 (1993).
- Saito et al., "Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins," *Proc. Natl. Acad. Sci. USA*, 85(7):2288-2292 (1988).
- Salgame et al., "Differing Lymphokine Profiles of Functional Subsets of Human CD4 and CD8 T Cell Clones," *Science*, 254(5029):279-282 (1991).
- Sambrook et al., *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., Title page, publication page, and table of contents only, 30 pages (1989).
- Schorey et al., "A *Mycobacterium leprae* Gene Encoding a Fibronectin Binding Protein Is Used for Efficient Invasion of Epithelial Cells and Schwann Cells," *Infect. Immun.*, 63(7):2652-2657 (1995).
- Schorey et al., "Characterization of the fibronectin-attachment protein of *Mycobacterium avium* reveals a fibronectin-binding motif conserved among mycobacteria," *Mol. Microbiol.*, 21(2):321-329 (1996).
- Sher et al., "Virulence of Six Strains of *Mycobacterium bovis* (BCG) in Mice," *Infect. Immun.*, 8(5):736-742 (1973).
- Shirakawa et al., "The Inverse Association Between Tuberculin Responses and Atopic Disorder," *Science*, 275(5296):77-79 (1997).

- Smith et al., "A National Estimate of the Economic Costs of Asthma," *Am. J. Respir. Crit. Care Med.*, 156(3):787-793 (1997).
- Swain et al., "IL-4 directs the development of Th2-like helper effectors," *J. Immunol.*, 145(11):3796-3806 (1990).
- Takatsu et al., "Antigen-Induced T Cell-Replacing Factor (TRF) I. Functional Characterization of a TRF-Producing Helper T Cell Subset and Genetic Studies on TRF Production," *J. Immunol.*, 124(5):2414-2422 (1980).
- Tatusova et al., "BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences," *FEMS Microbiol. Lett.*, 174(2):247-250 (1999).
- Wakeham et al., "Lack of Both Types 1 and 2 Cytokines, Tissue Inflammatory Responses, and Immune Protection During Pulmonary Infection by *Mycobacterium bovis* Bacille Calmette-Guerin in IL-12-Deficient Mice," *J. Immunol.*, 160(12):6101-6111 (1998).
- Walker et al., "Allergic and Nonallergic Asthmatics Have Distinct Patterns of T-Cell Activation and Cytokine Production in Peripheral Blood and Bronchoalveolar Lavage," *Am. Rev. Respir. Dis.*, 146(1):109-115 (1992).
- Walsh et al., "IL-5 enhances the in vitro adhesion of human eosinophils but not neutrophils in a leucocyte integrin (CD 11/18)-dependent manner," *Immunol.*, 71:258-265 (1990).
- Wierenga et al., "Evidence for compartmentalization of functional subsets of CD4⁺ T lymphocytes in atopic patients," *J. Immunol.*, 144(12):4651-4656 (1990).
- Wills-Karp et al., "Interleukin-13: Central Mediator of Allergic Asthma," *Science* 282(5397):2258-2261 (1998).
- Zhao et al., "Characterization of the Fibronectin Binding Motif for a Unique Mycobacterial Fibronectin Attachment Protein FAP," *J. Biol. Chem.*, 274(8):4521-4526 (Feb., 1999; published on-line Feb. 19, 1999).
- Zhao et al., "Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced anti-tumor activity," *Int. J. Cancer*, 86(1):83-88 (Apr. 1, 2000).

* cited by examiner

SEQ ID NO: 1:
 CACCCACCAACACGCCAGTTCATGAGCCGACCCGCGCCGTCCTTGCGTCGCGCCGTTAA 60
HpaI

SEQ ID NO: 2: M H O V D P N L T R R K G R
 CACGGTAGGTTCTTCGCCATGCATCAGGTGGACCCCAACTTGACACGTGCAAGGGACGA 120

L A A L A I A A M A S A S L V T V A V P
 TTGGCGGCACTGGCTATCGCGGCGATGGCCAGCGCCAGCCTGGTGACCCTTGCGGTGCC 180

A T A N A D P E P A P P V P T T A A S P
 GCGACCGCCAACGCCGATCCGGAGCCAGCGCCCCCGGTACCACACAACGGCCGCCTCGCCG 240
KpnI

P S T A A A P P A P A T P V A P P P P A
 CCGTCGACCGCTGCAGCGCCACCCGCACCGGCGACACCTGTTGCCCCCCCACCACCGGCC 300

A A N T P N A Q P G D P N A A P P P A D
 GCCGCCAACACGCCGAATGCCAGCCGGGCGATCCCAACGCAGCACCTCCGCCGGCCGAC 360

P N A P P P P V I A P N A P Q P V R I D
 CCGAACGCACCGCCGCCACCTGTCATTGCCCAAACGCACCCCAACCTGTCCGGATCGAC 420

N P V G G F S F A L P A G W V E S D A A
 AACCCGGTTGGAGGATTCAGCTTCGCGCTGCCTGCTGGCTGGGTGGAGTCTGACGCCGCC 480

H L D Y G S A L L S K T T G D P P F P G
 CACCTCGACTACGGTTCAGCACTCCTCAGCAAACCACCGGGACCCGCCATTTCCCGGA 540

Q P P P V A N D T R I V L G R L D Q K L
 CAGCCGCCGCCGGTGGCCAATGACACCCGTATCGTGCTCGGCCGGCTAGACCAAAGCTT 600

Y A S A E A T D S K A A A R L G S D M G
 TACGCCAGCGCCGAAGCCACCGACTCCAAGGCCGCGGCCCGGTGGGCTCGGACATGGGT 660

E F Y M P Y P G T R I N Q E T V S L D A
 GAGTTCATATATGCCCTACCCGGGCACCCGGATCAACCAGGAAACCGTCTCGCTCGACGCC 720

N G V S G S A S Y Y E V K F S D P S K P
 AACGGGGTGTCTGGAAGCGCTCGTATTACGAAGTCAAGTTCAGCGATCCGAGTAAGCCG 780

N G Q I W T G V I G S P A A N A P D A G
 AACGGCCAGATCTGGACGGCGTAATCGGCTCGCCCGCGGCGAACGCACCGGACGCCGGG 840

P P Q R W F V V W L G T A N N P V D K G
 CCCCTCAGCGCTGGTTTGTGGTATGGCTCGGGACCGCCAACAACCCGGTGGACAAGGGC 900

A A K A L A E S I R P L V A P P P A P A
 GCGGCCAAGGCGCTGGCCGAATCGATCCGGCCTTTGGTGCSCCCGCGCCGGCGCCGGCA 960

P A P A E P A P A P A P A G E V A P T P
 CCGGCTCCTGCAGAGCCCGCTCCGGCGCCGGCGCCGGCCGGGGAAGTCGCTCCTACCCCG 1020

T T P T P Q R T L P A
 ACGACACCGACACCGCAGCGGACCTTACCGGCCTGACCGGATCCGGCCGCACCCCAAGTG 1080

ATACCCCTGGGCGGGGTGTCAGCGCGGCCGGGCGCTCTTGAGC 1123

Fig. 1




Fig. 2




Fig. 3A




Fig. 3B




Fig. 4




Fig. 6A




Fig. 6B




Fig. 7A




Fig. 7B




Fig. 7C




Fig. 7D




Fig. 7E




Fig. 8

METHOD FOR INHIBITING INFLAMMATORY RESPONSES

CONTINUING APPLICATION DATA

This application claims the priority of U.S. Provisional Application Ser. No. 60/121,177, filed Feb. 22, 1999, which is incorporated by reference herein.

GOVERNMENT FUNDING

The present invention was made with government support under Grant No. RO1 HL59324 and RO1 CA44426, awarded by the National Institutes of Health. The Government has certain rights in this invention.

BACKGROUND

Asthma has attracted a great deal of attention from both the public and from the medical community in the past few years. It has been termed an "epidemic," and been the subject of cover stories in major newspapers and magazines. This is primarily due to the observation that the disease is worsening, particularly in Western, industrialized nations. In the past three decades, the prevalence, severity, and mortality of asthma have increased significantly. A recent study estimated the total annual cost in the United States at almost \$6 billion. Once thought to be due to airway muscle spasm, asthma is now known to be an inflammatory disorder; during an asthma exacerbation, inflammation precedes bronchospasm. In acute asthma, eosinophils may form up to half of the cellular infiltrate, and bronchoalveolar eosinophilia invariably follows allergen inhalation in asthma attacks. Eosinophils cause inflammation and bronchial hyperreactivity through release of mediators such as leukotrienes, major basic protein, eosinophilic cationic protein, and eosinophilic peroxidase (Bruijnzeel, *Ann NY Acad Sci* 725, 259-267, (1994)).

Numbers and activity of eosinophils are controlled by cytokines released from activated T cells, especially IL-4, IL-5, and IL-13. T-lymphocytes can be divided on the basis of cytokine production, into Th1 and Th2 (Mosmann, T. R. et al., *J. Immunol.*, 136, 2348-2357, (1986)). Th1 cells produce IL-2 and IFN- γ , but no IL-4 or IL-5, and Th2 cells produce IL-4, IL-5, IL-6, IL-10, and IL-13 but no IL-2 or IFN- γ . Th1 and Th2 cells interact in a counterregulatory fashion: IL-4 and IL-10 promote Th2 development (Parronchi et al., *J. Immunol.*, 149, 2977-2983 (1992), Swain et al., *J. Immunol.*, 145, 3796-3806 (1990)) and inhibit Th1 cell and cytokine production (Moore, K. W. et al., *Science*, 248, 1230-1234 (1990)), and IFN- γ inhibits the proliferation of Th2 cells (Gajewski et al., *J. Immunol.*, 140, 4245-4252 (1988)) and promotes the development of Th1 cells (Parronchi et al., *J. Immunol.*, 149 2977-2983 (1992)). IL-12, mainly a product of activated macrophages, is also a strong promoter of Th1 responses (Bliss, et al., *J. Immunol.*, 156, 887-894 (1996)) and is often considered a Th1 cytokine; many of the activities ascribed to IL-12 are due to induction of IFN- γ . Th1 and Th2 cells have been identified in humans, in vivo as well as in vitro.

The Th2 cytokines, IL-4, IL-5, and IL-13 (Grunig, et al., *Science*, 282, 2261-2263 (1998), Robinson et al., *N. Engl. J. Med.*, 326, 298-304 (1992), Wills-Karp et al., *Science*, 282, 2258-2261 (1998)), have been increasingly implicated in the inflammation of asthma. IL-4 amplifies allergic responses by inducing IgE production by uncommitted B-cells (Del Prete, et al., *J. Immunol.*, 140, 4193-8 (1988)) and is a growth factor for mast cells (Saito, et al., *Proc. Natl.*

Acad. Sci. USA, 85, 2288-2292 (1988)). IL-5 also stimulates immunoglobulin secretion (Swain, et al., *J. Immunol.*, 145, 3796-3806 (1990), Takatsu et al., *J. Immunol.*, 124, 2414-2422 (1980)) as well as stimulating the proliferation and activation of eosinophils (Clutterbuck, et al., *Blood* 73, 1504-1512 (1988), Lopez et al., *J. Exp. Med.*, 167, 219-223 (1988), Walsh et al., *Immunol.*, 71, 258-265 (1990)) and basophils (Hirai, K. et al., *J. Exp. Med.*, 172, 1525-1528 (1990)). IL-13 has recently been shown to cause airway hyperresponsiveness and inflammation independently of eosinophils or IL-4 (Grunig et al., *Science*, 282, 2261-2263 (1998), Wills-Karp et al., *Science*, 282, 2258-2261 (1998)). In vitro, allergen-specific T-cell clones from atopic donors release Th2 cytokines after stimulation by specific allergens (Parronchi et al., *Proc. Natl. Acad. Sci. USA*, 88, 4538-4542 (1991)). During asthma exacerbations, peripheral T-cell activation and increased serum IL-5 correlate with eosinophilia and asthma symptoms (Corrigan et al., *Am. Rev. Respir. Dis.*, 147, 540-547 (1993)), and bronchoalveolar lavage (BAL) T-cells release cytokines in a Th2-like pattern (Robinson et al., *J. All. Clin. Immunol.*, 92, 313-324 (1993)), Robinson et al., *N. Engl. J. Med.*, 326, 298-304 (1992), Robinson et al., *J. All. Clin. Immunol.*, 92, 397-403 (1993)). Non-atopic asthmatics also have increased levels of Th2-like cytokines; increased IL-5 release from BAL T-lymphocytes is characteristic of both atopic and non-atopic asthmatics (Walker et al., *Am. Rev. Respir. Dis.*, 146, 109-115 (1992)), and expression of peripheral T-cell IL-5 mRNA from non-atopic asthmatic subjects correlates with increased BAL (Marini et al., *Chest* 102, 661-669 (1992)) and peripheral blood (Walker et al., *Am. Rev. Respir. Dis.*, 146, 109-115 (1992)) eosinophilia.

Because of these observations, the focus of treatment in asthma has shifted from primarily addressing bronchospasm, to one of modulating inflammation. Recent guidelines to the management of asthma recommend that anti-inflammatory therapy be used for all but the most intermittent and benign cases of the disease. Current anti-inflammatory therapy, however, remains disappointingly broad and nonspecific; corticosteroids are the "gold standard" for asthma treatment, and inhaled corticosteroids are only incrementally better than they were 25 years ago. The much-touted leukotriene pathway antagonists which have been released in the last five years have been helpful only in a subset of asthmatics.

SUMMARY OF THE INVENTION

Positive tuberculin skin tests are associated with protection against atopy and asthma (Shirakawa et al., *Science*, 275, 77-79 (1997)) as well as systemic Th1 responses; however, the antigen(s) responsible for this protection has not been identified. The Fibronectin Attachment Protein of *Mycobacterium bovis*-BCG (FAP-B) has been identified and cloned. FAP-B is responsible for binding of the organism to fibronectin and for epithelial entry. Other FAPs have been isolated (*M. vaccae* FAP-V) and in some cases cloned (*M. leprae* FAP-L and *M. avium* FAP-A). Functional studies show FAP-B to bind fibronectin via the highly conserved attachment regions previously identified for FAP-A and FAP-L and also to competitively inhibit attachment of BCG to matrix fibronectin.

Surprisingly and unexpectedly, the FAP-B polypeptide is capable of protecting against the induction of an atopic/asthmatic inflammatory response. FAP-B and related polypeptides offer potential therapeutic benefit in asthma. Without intending to be bound by theory, it is expected that the mechanism of action through which FAP-B offers pro-

tection against Th2-mediated responses is through induction of Th1 responses, such as IFN- γ and IL-12, which can downregulate Th2 responses.

Accordingly, the present invention provides methods for treating at least one symptom of an inflammatory response in a mammal. In one embodiment, a method includes administering an effective amount of a microbial polypeptide to the mammal such that at least one symptom of an inflammatory response, for instance a Th2 mediated inflammatory response, is inhibited. Optionally, the microbial polypeptide is isolated. The microbial polypeptide can be administered prior to exposure to at least one suspected or known inflammation response-inducing agent, or administered during or after exposure to at least one suspected or known inflammation response-inducing agent.

The microbial polypeptide can be encoded by a nucleotide sequence, where the complement of the nucleotide sequence hybridizes to the nucleotide sequence set forth at nucleotides 79 to 1056 of SEQ ID NO:1 in a solution containing 50% formamide, 6 \times SSC, 7 \times Denhardt's reagent, 0.7% SDS, 150 μ g/ml salmon sperm DNA at 42 $^{\circ}$ C. for at least about 12 hours, followed by one wash for 30 minutes at 25 $^{\circ}$ C. in a solution containing 1 \times SSC, one wash for 30 minutes at 42 $^{\circ}$ C. in a solution containing 1 \times SSC, and one wash for 30 minutes at 42 $^{\circ}$ C. in a solution containing 0.1 \times SSC. For instance, the nucleotide sequence encoding the microbial polypeptide can be nucleotides 79 to 1056 of SEQ ID NO:1. The microbial polypeptide can also inhibit fibronectin attachment to bacillus Calmette-Guerin in a dose-dependent manner.

The microbial polypeptide can be a Mycobacterial polypeptide. The amino acid sequence of the Mycobacterial polypeptide can be the amino acid sequence of SEQ ID NO:2, GenBank accession AAB34676, GenBank accession AAB50543, GenBank accession CAA56555, GenBank accession AAB36458, GenBank accession P46842, or active analogs and active fragments thereof. Alternatively, the amino acid sequence of the Mycobacterial polypeptide can include amino acids 47 to 325 of SEQ ID NO:2, amino acids 112 to 283 of SEQ ID NO:2, 121 to 283 of SEQ ID NO:2, or active analogs and active fragments thereof. In another alternative, the amino acid sequence of the Mycobacterial polypeptide can be SEQ ID NO:3 and amino acids 47 to 325 of SEQ ID NO:2, and active analogs and active fragments thereof, wherein the carboxy terminal amino acid of SEQ ID NO:3 is fused to the amino terminal amino acid of amino acids 47 to 325 of SEQ ID NO:2.

The inflammatory response can be associated with a disease including skin allergy, hives, allergic rhinitis, conjunctivitis, hay fever, asthma, or allergic gastroenteritis. The types of asthma include extrinsic asthma and intrinsic asthma. When the asthma is extrinsic, it can be allergic asthma, occupational asthma, and allergic bronchopulmonary aspergillosis. When the asthma is intrinsic, it can be associated with an irritant including a pathogen, for instance a pathogen that causes a respiratory tract infection in the mammal, or an inhaled pollutant.

Another aspect of the invention provides a method for treating at least one symptom of an inflammatory response, including asthma, in a mammal including administering to the mammal a polypeptide such that at least one symptom of the inflammatory response is inhibited. The amino acid sequence of the polypeptide is SEQ ID NO:3 and amino acids 47 to 325 of SEQ ID NO:2, and active analogs and active fragments thereof, where the carboxy terminal amino acid of SEQ ID NO:3 is fused to the amino terminal amino acid of amino acids 47 to 325 of SEQ ID NO:2.

The present invention also provides an inflammation reaction inhibiting composition that includes a microbial polypeptide, for instance a Mycobacterial polypeptide, and a pharmaceutically acceptable carrier. In one embodiment, the polypeptide can comprise an amino acid sequence of SEQ ID NO:3 and amino acids 47 to 325 of SEQ ID NO:2, and active analogs and active fragments thereof, where the carboxy terminal amino acid of SEQ ID NO:3 is fused to the amino terminal amino acid of amino acids 47 to 325 of SEQ ID NO:2. In an alternative embodiment, the polypeptide is encoded by a nucleotide sequence, where the complement of the nucleotide sequence hybridizes to the nucleotide sequence set forth at nucleotides 79 to 1056 of SEQ ID NO:1 in a solution containing 50% formamide, 6 \times SSC, 7 \times Denhardt's reagent, 0.7% SDS, 150 μ g/ml salmon sperm DNA at 42 $^{\circ}$ C. for at least about 12 hours, followed by one wash for 30 minutes at 25 $^{\circ}$ C. in a solution containing 1 \times SSC, one wash for 30 minutes at 42 $^{\circ}$ C. in a solution containing 1 \times SSC, and one wash for 30 minutes at 42 $^{\circ}$ C. in a solution containing 0.1 \times SSC.

The present invention further provides a method for treating symptoms of an inflammatory response in a mammal, including administering an effective amount of a polypeptide to the mammal such that at least one symptom of an inflammatory response is inhibited. The polypeptide is encoded by a nucleotide sequence, where the complement of the nucleotide sequence hybridizes to the nucleotide sequence set forth at nucleotides 79 to 1056 of SEQ ID NO:1 in a solution containing 50% formamide, 6 \times SSC, 7 \times Denhardt's reagent, 0.7% SDS, 150 μ g/ml salmon sperm DNA at 42 $^{\circ}$ C. for at least about 12 hours, followed by one wash for 30 minutes at 25 $^{\circ}$ C. in a solution containing 1 \times SSC, one wash for 30 minutes at 42 $^{\circ}$ C. in a solution containing 1 \times SSC, and one wash for 30 minutes at 42 $^{\circ}$ C. in a solution containing 0.1 \times SSC.

Definitions

"Treating" refers to the administration of a polypeptide or a composition that includes a polypeptide at any time prior to the onset of at least one symptom of an inflammatory response, i.e., prophylactic therapy. "Treating" also refers to the administration of a polypeptide or a composition that includes a polypeptide during or after the onset of at least one symptom of an inflammatory response to ameliorate at least one symptom of an inflammatory response. In other words, "treating" refers to both the prevention (prophylactic) and to the amelioration (therapeutic) of at least one symptom of an inflammatory response.

Inflammatory response, and symptoms of an inflammatory response are described in greater detail herein. An inflammatory response-inducing agent is a substance that induces an inflammatory response in a mammal. Non-limiting examples of inflammatory response-inducing agents include allergens, particulates, pathogens, and pollutants such as tobacco smoke. "Exposure" to inflammatory response-inducing agents indicates that a mammal is in an environment where inflammatory response-inducing agents are present or may be present.

An "effective amount" of a polypeptide refers to an amount of the polypeptide that is sufficient to inhibit in a mammal at least one symptom of an inflammatory response.

"Polypeptide" as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like.

A polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized. A "microbial polypeptide" refers to a polypeptide that is expressed by a microbe, is encoded by a coding region isolated from a microbe, is encoded by a coding region that hybridizes with a nucleotide sequence as described in greater detail herein or that has a certain percentage structural similarity with a nucleotide sequence as described in greater detail herein, or has a certain percentage structural similarity with a polypeptide as described herein. A type of microbial polypeptide is "mycobacterial polypeptide," where "mycobacterial" refers to a strain of the genus *Mycobacterium*. A coding region refers to a polynucleotide that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end.

An active analog or active fragment of a polypeptide is one that retains the ability to treat the symptoms of an inflammatory response in an animal as described herein. Active analogs and active fragments are described in greater detail herein.

The term "complement" and "complementary" as used herein, refers to the ability of two single stranded polynucleotides to base pair with each other, where an adenine on one polynucleotide will base pair to a thymine on a second polynucleotide and a cytosine on one polynucleotide will base pair to a guanine on a second polynucleotide. Two polynucleotides are complementary to each other when a nucleotide sequence in one polynucleotide can base pair with a nucleotide sequence in a second polynucleotide. For instance, 5'-ATGC and 5'-GCAT are complementary. The terms complement and complementary also encompass two polynucleotides where one polynucleotide contains at least one nucleotide that will not base pair to at least one nucleotide present on a second polynucleotide. For instance the third nucleotide of each of the two polynucleotides 5'-ATTGC and 5'-GCTAT will not base pair, but these two polynucleotides are complementary as defined herein. Typically two polynucleotides are complementary if they hybridize under certain conditions.

As used herein, "hybridizes," "hybridizing," and "hybridization" means that a single stranded polynucleotide forms a noncovalent interaction with a complementary polynucleotide under certain conditions, as described herein.

Unless noted otherwise, a "pathogen" as used herein refers to a virus or a microbe, including prokaryotic microbes and eukaryotic microbes, that is capable of causing a respiratory tract infection in a mammal, whether the mammal is immunocompromised or not. The terms "bacillus Calmette-Guerin" and *M. bovis* BCG are used interchangeably and refer to a strain of *M. bovis* that has been rendered completely avirulent.

An "isolated" polypeptide or polynucleotide means a polypeptide or polynucleotide that has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized. Preferably, a polypeptide or polynucleotide of this invention is purified, i.e., essentially free from any other polypeptide or polynucleotide and associated cellular products or other impurities.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Nucleotide sequence (SEQ ID NO:1) and amino acid sequence (SEQ ID NO:2) of FAP-B. The signal sequence is underlined; the first 17 amino acids (amino acids

40-56 of SEQ ID NO:2) corresponding to BCG 45/47 kDa antigen are in bold.

FIG. 2. Binding of purified FAP-B, FAP-A, and control recombinant β -galactosidase (β -gal) to fibronectin.

FIG. 3. Effect of anti-fibronectin, anti-FAP, and FAP-A₂₆₉₋₂₉₂ peptide on FAP-B binding to fibronectin (FN). A. Inhibition of FAP-B binding to fibronectin by anti-FN and anti-FAP antibodies. B. Inhibition of FAP-B binding to fibronectin by synthesized FAP-A₂₆₉₋₂₉₂. BSA as ligand, only BSA added to wells; control peptide, the random sequence of the amino acids in the FAP-A₂₆₉₋₂₉₂.

FIG. 4. Effect of FAP-A, FAP-B, and FAP-A₂₆₉₋₂₉₂ on the in vitro attachment of BCG to fibronectin. Max, binding of BCG to fibronectin coated surfaces in the absence of added proteins or peptides; Min, BCG retention on human serum albumin coated surfaces; Control peptide, the random sequence of the amino acids in the FAP-A₂₆₉₋₂₉₂; Con J, control J.

FIG. 5. Ovalbumin murine model of asthma. ip, interperitoneal.

FIG. 6. Lung eosinophilia and cell differential in murine model of asthma in presence or absence of FAP-B. FAP-B, mice that received FAP-B alone and were not sensitized to ovalbumin; FAP-B/OVA, mice that received FAP-B immediately prior to sensitization to ovalbumin; OVA, mice that were sensitized to ovalbumin and did not receive FAP-B. A. Number of eosinophils in lavage fluid. B. Effect of FAP-B on cell differential in lavage fluid. Alv Mac, alveolar macrophages; Ly, lymphocytes; PMN, polymorphonucleocytes; Eo, eosinophils.

FIG. 7. Airway responsiveness to inhaled methacholine at pre- and post-immunotherapy. FAP-B, mice that received FAP-B alone and were not sensitized to ovalbumin; FAP-B/OVA, mice that received FAP-B immediately prior to sensitization to ovalbumin; OVA, mice that were sensitized to ovalbumin and did not receive FAP-B; Penh, see description in Example 6; baseline, whole body plethysmograph at the start of the study on Day-1; final, whole body plethysmograph at the end of the study. A. Results of whole body plethysmograph of mice in each of the three groups of mice at the start of the study. B. Results of whole body plethysmograph of mice in each of the three groups of mice at the end of the study. C. Methacholine responsiveness in FAP-B mice. D. Methacholine responsiveness in FAP-B/OVA mice. E. Methacholine responsiveness in OVA mice.

FIG. 8. Antigen-stimulated release of cytokines by murine splenocytes. At the time of sacrifice, splenocytes were isolated from each mouse and cultured in the presence of antigen (ovalbumin, 40 μ g/100 μ l well). FAP-B, mice that received FAP-B alone and were not sensitized to ovalbumin; FAP-B/OVA, mice that received FAP-B immediately prior to sensitization to ovalbumin; OVA, mice that were sensitized to ovalbumin and did not receive FAP-B; control, mice injected with saline.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods for inhibiting at least one symptom of an inflammatory response in a mammal, preferably a mouse or a human, most preferably a human. The methods include administering an effective amount of a polypeptide, preferably a microbial polypeptide, more preferably a Mycobacterial polypeptide, to a mammal. The polypeptides that can be used in the methods are described in greater detail herein. The administration causes the inhibition of at least one symptom of an inflammatory

response in the mammal. Preferably, the at least one symptom is the result of an inflammatory response in which Th2 cells release cytokines, including for example, IL4, IL-5, IL-8, and IL-13, that regulate the inflammatory response. Such an inflammatory response is referred to herein as a Th2 mediated inflammatory response.

Examples of symptoms of an inflammatory response, preferably a Th2 mediated inflammatory response, include, for instance, those associated with skin allergy, hives, allergic rhinitis, conjunctivitis, eczema, hay fever, asthma, or allergic gastroenteritis, pulmonary eosinophilia, eosinophilic-myalgia syndrome, tropical eosinophilia, hypereosinophilic syndrome, and Churg-Strauss syndrome, and parasitic infections, including schistosomiasis, preferably asthma. Other symptoms of an inflammatory response can include pain, swelling, redness, warmth, and itching.

The types of asthma include extrinsic asthma (e.g., asthma initiated by an inhaled antigen) and intrinsic asthma (e.g., asthma initiated by non-immune mechanisms), for example. Types of extrinsic asthma include, for instance, allergic asthma, occupational asthma, and allergic bronchopulmonary aspergillosis. Extrinsic asthma is typically associated with a specific immune response to an antigen (e.g., IgE interacting with an antigen). Intrinsic asthma includes asthma associated with an irritant, for instance, a pathogen, preferably a pathogen that can or has caused a respiratory tract infection in the mammal. Non-limiting examples of pathogens that have been associated with the development and/or progression of asthma include respiratory syncytial virus, coronavirus, parainfluenza virus, and rhinovirus. Other irritants associated with intrinsic asthma include, for instance, inhaled pollutants such as respirable particulates, environmental tobacco smoke, ozone, SO₂, and NO₂.

Symptoms of asthma include airway inflammation, which typically causes other symptoms including airway hyperresponsiveness and airflow limitation (National Asthma Education and Prevention Program, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, Bethesda, Md., National Institutes of Health, pp. 7-13, (1997)). Measurement of the symptoms of asthma includes evaluating the presence of denudation of airway epithelium, collagen deposition beneath basement membrane, edema, mast cell activation, inflammatory cell infiltration including neutrophils, eosinophils, and lymphocytes, and the presence of cytokines associated with Th2 cells including IL-4, IL-5, IL-9, and IL-13. Preferably, eosinophil infiltration is measured. Methods known to the art can be used to access the airway and measure symptoms associated with asthma, including, for instance, fiberoptic bronchoscopy, lavage, or biopsy (Beasley et al., *Am. Rev. Respir. Dis.*, 139, 806-817 (1989), Jeffery et al., *Am. Rev. Respir. Dis.*, 140, 1745-1753 (1989), and Laitinen et al., *Am. Rev. Respir. Dis.*, 131, 599-606 (1985)). Measurement of airway hyperresponsiveness includes inhalation challenge testing with methacholine, or histamine (O'Connor et al., *Am. Rev. Respir. Dis.*, 140, 225-252 (1989)). Airway hyperresponsiveness can also be measured after hyperventilation with cold dry air, inhalation of hypotonic or hypertonic aerosols, or after exercise (O'Connor et al., *Am. Rev. Respir. Dis.*, 140, 225-252 (1989)). Variability between morning and evening peak expiratory flow may also be used as a measure of airway hyperresponsiveness.

The present invention further provides a pharmaceutical composition that includes a polypeptide, preferably a microbial polypeptide, more preferably a Mycobacterial polypeptide, that is useful in the methods of the present invention, and a pharmaceutically acceptable carrier. The

compositions of the present invention are formulated in pharmaceutical preparations in a variety of forms adapted to the chosen route of administration. Formulations include those suitable for parenteral administration or for perfusion.

The formulations may be conveniently presented in unit dosage form and may be prepared by methods well known in the art of pharmacy. Typically, methods of preparing a pharmaceutical composition include the step of bringing the active compound (e.g., a polypeptide useful in the methods of the present invention) into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulations.

The polypeptides of the invention can be incorporated directly into the food of a mammal's diet, as an additive, supplement, or the like. Thus, the invention further provides a food product containing a polypeptide of the invention. Any food is suitable for this purpose, although processed foods already in use as sources of nutritional supplementation or fortification, such as breads, cereals, milk, and the like, may be more convenient to use for this purpose.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the composition, or dispersions of sterile powders that include the composition, which are preferably isotonic with the blood of the recipient. Isotonic agents that can be included in the liquid preparation include sugars, buffers, and sodium chloride. Solutions of the composition can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions of the composition can be prepared in water, ethanol, a polyol (such as glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, glycerol esters, and mixtures thereof. The ultimate dosage form is sterile, fluid, and stable under the conditions of manufacture and storage. The necessary fluidity can be achieved, for example, by using liposomes, by employing the appropriate particle size in the case of dispersions, or by using surfactants. Sterilization of a liquid preparation can be achieved by any convenient method that preserves the bioactivity of the composition, preferably by filter sterilization. Preferred methods for preparing powders include vacuum drying and freeze drying of the sterile injectable solutions. Subsequent microbial contamination can be prevented using various antimicrobial agents, for example, antibacterial, antiviral, and antifungal agents including parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Absorption of the composition by the mammal over a prolonged period can be achieved by including agents for delaying, for example, aluminum monostearate and gelatin.

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredients including diluents, buffers, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.

The formulations include those suitable for parenteral administration including subcutaneous, intramuscular, intraperitoneal, intravenous, and aerosol administration. Preferably, the composition of the invention is administered intravenously, or by aerosol. Aerosols can be delivered by, for instance, oral and/or nasal inhalation from a metered dose inhaler. Useful dosages of the compositions can be determined by comparing their in vitro activity and the in vivo activity in animal models. Methods for extrapolation of

effective dosages in mice, and other mammals, to humans are known in the art; for example, see Borch et al. (U.S. Pat. No. 4,938,949).

Polypeptides and Polynucleotides

A polypeptide of the present invention is typically capable of inhibiting at least one symptom of an inflammatory response in a mammal, preferably a Th2 mediated response. Optionally, a polypeptide of the invention is also able to specifically inhibit attachment of fibronectin to bacillus Calmette-Guerin. The ability to inhibit at least one symptom of an inflammatory response, and the specific inhibition of fibonectin attachment to bacillus Calmette-Guerin, can be measured as described herein. A polypeptide can be present in, for instance, a cell lysate, or the polypeptide can be isolated or purified. Preferably, the polypeptide is isolated, more preferably, purified.

The polypeptides useful in some aspects of the invention are produced by a prokaryotic microbe, and more preferably a strain of the genus *Mycobacterium*, including, for instance, *M. leprae*, *M. vaccae*, *M. tuberculosis*, *M. avium*, *M. smegmatis*, *M. kansasii*, *M. bovis*, and *M. bovis* BCG. Preferably, the Mycobacterial polypeptide is produced by *M. bovis* BCG. Examples of Mycobacterial polypeptides useful in the methods of the present invention include the Fibronectin Attachment Proteins (FAPs), including FAP-L

1 MNQVDLDSTH RKGLWAILAI AVVASASAFT
 MPLPAAANAD PAPLPPSTAT AAPSPAQEI
 61 TPLPGAPVSS EAQPGDPNAP SLDPNAPYPL AVDP-
 NAGRIT NAVGGFSFVL PAGWVESEAS
 121 HLDYGSVLLS KAIEQP PVLG QPTVVATDTR
 IVLGRLDQKL YASAEADNIK AAVRLGSDMG
 181 EFYLPYPGTR INQETIPLHA NGIAGSASY
 EVKFSDPNKP IGQICTSVVG SPAASTPDVG
 241 PSQRWFVVWL GTSNNPVDKG AAKELAESIR
 SEMAPIASV SAPAPVG

(which is produced by *M. leprae* and depicted at SEQ ID NO:4, and GenBank accession No. AAB34676), FAP-A

1 MDQVEATSTR RKGLWTTLAI TTVSGASAVV IAL-
 PETSHAD PEVPTPVPPS TATTPHRRR
 61 RIPGQPADNA QAGAPAPAPN GQQRPPRRR MIP-
 TRAPPPA GAPPNGAPPA APNGAPPPP
 121 DPNAPPPPPA DPNAGRIPNS YVLPAGWVES
 DASHLDYGSA LLSKVTGPPP MPDQPPVAN
 181 DTRIVMGRVD QKLYASAEAN NAKAAVGLGS
 DMGEFFMPYP GTRINQDSTP LNGANGSTGS
 241 ASYYEVKFSK ASKPNGQIWT GVIKSANAGN
 RQRWFVVWL GTSNDPVDKVA AKALAESIQ
 301 WTPPPAPPAA PGGPGAPAPG APGAPAPGAP
 AAPGVTAPAA PAPAAPGAPA APGAPAPEPG
 361 QAPAVEVSPT PTPTPQQTLS A

(which is produced by *M. avium* and depicted at SEQ ID NO:5, and GenBank accession No. AAB50543), and FAP-B (which is produced by *M. bovis* BCG and depicted at SEQ ID NO:2, and GenBank accession No. AAB71842). Other examples of Mycobacterial polypeptides useful in the methods of the present invention include the *M. tuberculosis* 45/47 protein

1 MHQVDPNLTR RKGRLAALAI AAMASASLVT VAV-
 PATANAD PEPAPPVPTT AASPSTAAA
 61 PPAPATPVAP PPPAAANTPN AQPDPNAAAP PPAD-
 PNAPP PVIAPNAPQP VRIDNPVGGF
 121 SFALPAGWVE SDAAHFDYGS ALLSKTTGDP
 PFPQPPPPVA NDTRIVLGR L DQKLYASAEA

181 TDSKAAARLG SDMGEFYMPY PGTRINQETV
 SLDANGVSGS ASYYEVKFSK PSKPNGQIWT
 241 GVIGSPAANA PDAGPPQRWF VVWLGATANNP
 VDKGAAKALA ESIRPLVAPP PAPAPAPAE
 301 APAPAPAGEV APTPTTPTPQ RTLPA

(depicted at SEQ ID NO:6, and GenBank accession No. CAA56555), the *M. tuberculosis* 45 kDa culture filtrate glycoprotein

1 DPEPAPPVPT TAASPPSTAA APPAPATPVA PPP-
 PAAANTP NAQPGDPNAA PPPADPNAPP
 61 PPVIAPNAPQ PVRIDNPVGG FFSALPAGWV
 ESDAAHFDYG SALLAKTTGD PFPQPPPPV
 15 121 ANDTRIVLGR LDQKLYASAE ATDSKAAARL
 GSDMGEFYMP YPGTRINQET VSLDANGVSG
 181 SASYYEVKFS DPSKPNGQIW TGVIKSPAAN
 APDAGPPQRW FVVWLGATANN PVDKGAAKAL
 241 AESIRPLVAP PPAPAPAPAE PAPAPAPAGE VAPTPT-
 TPTP QRTLPA

(depicted at SEQ ID NO:7, and GenBank accession No. AAB36458), and the *M. leprae* antigen 43L precursor

25 1 MNQVDLDSTH RKGLWAILAI AVVASASAFT
 MPFRAAANAD PAPLPPSTAT AAPSPAQEI
 61 TPLPGAPVSS EAQPGDPNAP SLDPNAPYPL AVDP-
 NAGRIT NAVGGFSFVL PAGWVESEAS
 121 HLDYGSVLLS KAIEQPPVLG QPTVVATDTR
 30 1VLGRLDQKL YASAEADNIK AAVRLGSDMG
 181 EFYLPYPGTR INQETIPLHA NGIAGSASY
 EVKFSDPNKP IGQICTSVVG SPAASTPDVG
 241 PSQRWFVVWL GTSNNPVDKG AAKELAESIR
 SEMAPIASV SAPAPVG

(depicted at SEQ ID NO:8, and GenBank No. accession P46842). Preferably, the Mycobacterial polypeptide is FAP-B (SEQ ID NO:2), more preferably amino acids 40-325 of SEQ ID NO:2, most preferably amino acids 47-325 of SEQ ID NO:2. Alternatively, the Mycobacterial polypeptide has the amino-terminal domain of amino acid sequence SEQ ID NO:3 (which is described herein) fused to amino acids 47 to 325 of SEQ ID NO:2.

Polypeptides useful in some aspects of the invention include those having a significant level of similarity with the amino acid sequence of SEQ ID NO:2, more preferably amino acids 40-325 of SEQ ID NO:2, most preferably amino acids 47-325 of SEQ ID NO:2. The similarity is referred to as structural similarity and is generally determined by aligning the residues of the two amino acid sequences (i.e., a candidate amino acid sequence and the amino acid sequence of SEQ ID NO:2) to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. A candidate amino acid sequence is the amino acid sequence being compared to an amino acid sequence present in the amino acid sequence of SEQ ID NO:2. A candidate amino acid sequence can be isolated from an organism, preferably a microbe, or can be artificially constructed by using, for instance, recombinant techniques, or chemically or enzymatically synthesized. Preferably, two amino acid sequences are compared using the Blastp program, version 2.0.9, of the BLAST 2 search algorithm, as described by Tatusova, et al. (*FEMS Microbiol Lett* 1999, 174:247-250), and available at

www.ncbi.nlm.nih.gov/gorf/b12.html. Preferably, the default values for all BLAST 2 search parameters are used, including matrix=BLOSUM62; open gap penalty=11, extension gap penalty=1, gap x_dropoff=50, expect=10, wordsize=3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, structural similarity is referred to as "identities." Preferably, a polypeptide includes an amino acid sequence having a structural similarity with the amino acid sequence of SEQ ID NO:2 of, in increasing order of preference, greater than 61% identity, at least about 70% identity, at least about 80% identity, most preferably at least about 90% identity.

Alternatively, a polypeptide useful in some aspects of the invention is encoded by a polynucleotide, the complement of which hybridizes to nucleotides 79 to 1056 of SEQ ID NO:1 under standard hybridization conditions as defined herein. Polynucleotides encoding polypeptides useful in some aspects of the invention also include those having a significant level of similarity with nucleotides 79 to 1056 of SEQ ID NO:1, i.e., the coding region present in SEQ ID NO:1. The similarity is referred to as structural similarity and is determined by aligning the residues of the two polynucleotides (i.e., the nucleotide sequence of the candidate nucleotide sequence and the nucleotides 79 to 1056 of SEQ ID NO:1) to optimize the number of identical nucleotides along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of shared nucleotides, although the nucleotides in each sequence must nonetheless remain in their proper order. A candidate nucleotide sequence is the sequence being compared to nucleotides 79 to 1056 of SEQ ID NO:1. Preferably, two nucleotide sequences are compared using the Blastn program, version 2.0.9, of the BLAST 2 search algorithm, as described by Tatusova, et al. (*FEMS Microbiol Lett* 1999, 174:247-250), and available at www.ncbi.nlm.nih.gov/gorf/b12.html. Preferably, the default values for all BLAST 2 search parameters are used, including reward for match=1, penalty for mismatch=-2, open gap penalty=5, extension gap penalty=2, gap x_dropoff=50, expect=10, wordsize=11, and filter on. In the comparison of two nucleotide sequences using the BLAST search algorithm, structural similarity is referred to as "identities." Preferably, a polynucleotide includes a nucleotide sequence having a structural similarity with nucleotides 79 to 1056 of SEQ ID NO:1 of, in increasing order of preference, greater than 61% identity, at least about 70% identity, at least about 80% identity, most preferably at least about 90% identity.

Optionally, individual organisms, preferably microbes, can be screened for the presence of polypeptides that specifically inhibit attachment of fibronectin to bacillus Calmette-Guerin. Typically, such polypeptides are isolated from a microbe as described in Example 1, and evaluated for the ability to specifically inhibit attachment of fibronectin to bacillus Calmette-Guerin as described in Example 5. Polypeptides identified in this way can be evaluated using the mammal model described in Example 6. Once a polypeptide is identified that decreases eosinophilia or decreases responsiveness to inhaled methacholine, the polypeptide can be used in the methods of the present invention, or the polynucleotide sequence encoding the polypeptide can be isolated using methods detailed herein.

The polypeptides useful in some aspects of the invention include an active analog and active fragment of SEQ ID NO:2, or GenBank accession Nos. AAB34676, AAB50543, CAA56555, AAB36458, or P46842. An active analog or active fragment of a polypeptide is one that is expressed by

a microbe and is able to inhibit at least one symptom of an inflammatory response in a mammal, and optionally specifically inhibit attachment of fibronectin to bacillus Calmette-Guerin. Active analogs of a polypeptide include polypeptides having amino acid substitutions that do not eliminate the ability to inhibit at least one symptom of an inflammatory response in a mammal, and optionally specifically inhibit attachment of fibronectin to bacillus Calmette-Guerin. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and vice versa to maintain a positive charge; Glu for Asp and vice versa to maintain a negative charge; Ser for Thr so that a free —OH is maintained; and Gln for Asn to maintain a free NH₂.

Active analogs, as that term is used herein, also include modified polypeptides. Modifications of polypeptides of the invention include chemical and/or enzymatic derivatizations at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C-terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

Active fragments of a polypeptide include a portion of the polypeptide containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will inhibit at least one symptom of an inflammatory response in a mammal, and optionally specifically inhibit attachment of fibronectin to bacillus Calmette-Guerin. A preferred example of an active fragment of SEQ ID NO:2 are amino acids 112 to 283, more preferably amino acids 121 to 283.

Alternatively, a polypeptide useful in some aspects of the invention is encoded by a polynucleotide, the complement of which hybridizes to nucleotides 79 to 1056 of SEQ ID NO:1 under standard hybridization conditions as defined herein. Polynucleotides encoding polypeptides useful in some aspects of the invention also include those having a significant level of similarity with nucleotides 79 to 1056 of SEQ ID NO:1, i.e., the coding region present in SEQ ID NO:1. The similarity is referred to as structural similarity and is determined by aligning the residues of the two polynucleotides (i.e., the nucleotide sequence of the candidate nucleotide sequence and the nucleotides 79 to 1056 of SEQ ID NO:1) to optimize the number of identical nucleotides along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of shared nucleotides, although the nucleotides in each sequence must nonetheless remain in their proper order. A candidate nucleotide sequence is the sequence being compared to nucleotides 79 to 1056 of SEQ ID NO:1. Preferably, two nucleotide sequences are compared using the Blastn program, version 2.0.9, of the BLAST 2 search algorithm, as described by Tatusova et al. (*FEMS Microbiol Lett* 1999, 174:247-250), and available at <http://www.ncbi.nlm.nih.gov/gorf/b12.html>. Preferably, the default values for all BLAST 2 search parameters are used, including reward for match=1, penalty for mismatch=-2, open gap penalty=5, extension gap penalty=2, gap x_dropoff=50, expect=10, wordsize=11,

and filter on. In the comparison of two nucleotide sequences using the BLAST search algorithm, structural similarity is referred to as "identities." Preferably, a polynucleotide includes a nucleotide sequence having a structural similarity with nucleotides 79 to 1056 of SEQ ID NO:1 of, in increasing order of preference, greater than 61% identity, at least about 70% identity, at least about 80% identity, most preferably at least about 90% identity.

Individual organisms, preferably microbes, can be screened for the presence of nucleotide sequences that are similar to nucleotides 79 to 1056 of SEQ ID NO:1. Screening methods include, for instance, hybridization of polynucleotides immobilized on a membrane with a detectably labeled probe. Standard hybridizing conditions use hybridization buffer containing 50% formamide, 6×SSC, 5× to 10×Denhardt's reagent, 0.5% to 1.0% SDS, 100 μg/ml to 200 μg/ml salmon sperm DNA containing labeled probe (1×SSC: 0.15 M NaCl, 0.015 M sodium citrate; 50×Denhardt's reagent: 1% Ficoll Type 400, 1% polyvinylpyrrolidone, and 1% bovine serum albumin Fraction V). preferably, the hybridization buffer contains 50% formamide, 6×SSC, 7×Denhardt's reagent, 0.7% SDS, 150 μg/ml salmon sperm DNA and labeled probe. Hybridization is allowed to occur at 42° C. for at least about 12 hours. The membrane is washed once for 30 minutes at 25° C. in a solution containing 1×SSC, once for 30 minutes at 42° C. in a solution containing 1×SSC, and once for 30 minutes at 42° C. in a solution containing 0.1×SSC. Generally the probe does not have to be complementary to all the nucleotides of a polynucleotide as long as there is hybridization under the conditions described herein.

Preferred probes for identifying polynucleotides encoding a polypeptide that inhibits at least one symptom of an inflammatory response in a mammal, and optionally specifically inhibits attachment of fibronectin to bacillus Calmette-Guerin are polynucleotides complementary to a portion of nucleotides 79 to 1056 of SEQ ID NO:1. A probe is typically no greater than about 975 bases and no less than about 10 bases. Methods of detectably labeling a probe are known to the art. The polynucleotide that is identified by the probe is further analyzed using methods known to one of ordinary skill in the art to determine if it encodes a polypeptide that inhibits at least one symptom of an inflammatory response in a mammal, and optionally specifically inhibits attachment of fibronectin to bacillus Calmette-Guerin. Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to a portion of nucleotides 79 to 1056 of SEQ ID NO:1 is the polymerase chain reaction (PCR). Primer pairs can be designed using methods known to the art that will amplify a portion of nucleotides 79 to 1056 of SEQ ID NO:1. Such a primer pair can be used to screen individual microorganisms for the presence of nucleotide sequences that are similar to nucleotides 79 to 1056 of SEQ ID NO:1.

A polynucleotide encoding a polypeptide useful in the methods of the present invention can be inserted in a vector. Construction of vectors containing a polynucleotide of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R. M., ed. *Current Protocols in Molecular Biology* (1994). A vector can provide for further cloning (amplification of the polynucleotide), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector. The term vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors. Typically, a vector

is capable of replication in a bacterial host, for instance *E. coli*. Preferably the vector is a plasmid. A vector containing a polynucleotide encoding a polypeptide useful in the methods of the present invention can be introduced to a microbe using methods known to the art. The appropriate method to use varies depending on the type of microbe, and include, for instance, CaCl₂ mediated transformation, electroporation, and transduction.

An expression vector optionally includes regulatory regions operably linked to the coding region. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Typically, a promoter results in greater expression of the operably linked coding region when compared to expression of the coding region when operably linked to its natural promoter. Preferred promoters for bacterial transformation include lac, lacUV5, tac, trc, T7, SP6 and ara.

An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. The polynucleotide used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is an often used terminator that is incorporated into bacterial expression systems (J. Brosius et al., (1981) *J. Mol. Biol.* 148 107-127).

A polynucleotide encoding a polypeptide useful in the invention can be altered by inserting a series of nucleotides in frame with the coding region, such that the resulting fusion polypeptide contains a polypeptide useful in the invention fused to an additional domain. This can be used to introduce domains that can facilitate the isolation of the polypeptide. For instance, domains useful in the isolation of a fusion polypeptide that contains a polypeptide useful in the invention include, for example, a histidine domain (which can be isolated using nickel-chelating resins), or an S-peptide domain (which can be isolated using an S-protein, see Kim, J.-S. et al. *Protein Sci.*, 2, 348-356 (1993)). Domains useful in targeting a polypeptide to the exterior surface of a cell, for instance a signal peptide, can also be introduced.

Optionally, the vector includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, and tetracycline.

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein, and are not intended to limit the invention in any way.

EXAMPLE 1

Isolation of a Fibronectin Attachment Protein (FAP) from *Mycobacterium*

A FAP polypeptide was isolated from *M. vaccae* and from *M. bovis* BCG as described in U.S. Pat. No. 5,618,916

(Ratliff et al.). The FAP polypeptides are referred to as p55 in this example.

Chemicals

All chemicals were purchased from Sigma (St. Louis, Mo.) and were reagent grade unless otherwise stated.

Bacteria

BCG were obtained from Armand Frappier, Quebec, Canada, as a lyophilized preparation containing 10^{sup.7} colony forming units (CFU) mg⁻¹ manufacturer's specification). Before use, BCG was cultured in Youman's medium or 5 d at 37° C. The bacteria were harvested by centrifugation and resuspended in buffer to produce approximately 7×10⁸ CFU ml⁻¹ (determined by standard curves plotting OD₅₇₀ vs CFU). *M. vaccae* was obtained from the mycobacterial culture collection of Dr. John Stanford, University of London, London, England. *M. vaccae* was grown in Sauton medium and stored at -70° C. as described. Sher et al., (*Infect and Immun.*, 8, 736-742 (1973)).

Preparation of ¹²⁵I-labelled Fibronectin (FN)

Human plasma FN was purified as previously described (Kavoussi et al., *J. Clin. Invest.*, 85, 62-67 (1990)). The purified FN, 1.5 mg ml⁻¹ was labelled for 15 minutes with 1 mCi (37 MBq) ¹²⁵INa (Amersham) in a test-tube pre-coated with 200 µg Iodo-Gen (1,3,4,6-tetrachloro-3,6-diphenylglycouril) as previously described. (Aslanzadeh et al., *J. Gen. Microbiol.*, 135, 2735-2741 (1989)). The labelled FN was then separated from unbound ¹²⁵I by chromatography on a 10 ml Sephadex G25 column. The specific activities of the labelled FN preparations were routinely between 10⁶ and 10⁷cpm µg⁻¹.

¹²⁵I-FN Binding Assay

The binding assay was performed as previously described. (Aslanzadeh et al., *J. Gen. Microbiol.*, 135, 2735-2741 (1989)). Briefly, six micrograms of ¹²⁵I-FN was added to 1.5 ml volume microcentrifuge tubes (Eppendorf) pre-coated for 2 hours with 1 ml of 1 mg/ml human serum albumin (HSA). Prior to ¹²⁵I-FN addition, 7×10⁶ BCG suspended in 1.0 ml of 0.1M-Tris buffer, pH 6.0, was added. The ¹²⁵I-FN was mixed with either 300 µl unlabelled FN (1 mg/ml) or 300 µl of TRIS only to determine non-specific and total binding, respectively. Specific binding was ascertained by subtracting non-specific from total binding. The reaction mixtures were incubated for 1 hour at 22° C. After incubation, the microcentrifuge tubes containing the reaction mixtures were centrifuged at 10,000 g for 3 minutes in a Beckman Microcentrifuge B. The supernatant, containing free radiolabelled FN, was carefully removed. The microcentrifuge tubes were sliced and the pellets containing the radiolabelled FN bound to BCG were analyzed for radioactivity. Control experiments using ¹²⁵I-FN without bacteria produced background counts of approximately 500 cpm.

Attachment of BCG to FN-coated Surfaces

The matrix attachment assay was performed by a modification of a previously described method. Ratliff et al., (*J. Gen. Microbiol.*, 134, 1307-1313 (1988)) Briefly, a 5 day culture was washed twice with and resuspended in phosphate-buffered saline (PBS), pH 7.2, to a concentration of 10⁸ CFU/ml. 10⁷ CFU (0.1 ml) was added to each well of a 96 well microtiter plate (Immulon II, Dynatech Laboratories, Inc., Chantilly, Va.) previously coated with (120 µg/ml) of FN or HSA (120 µg/ml; background). Attachment was quantitated by reading the optical density at 570 nm on an ELISA reader.

Production of Receptor-Containing Supernatants

M. vaccae were subcultured in 100 ml of Sautons medium to plateau growth phase. An inoculum of 8×10⁸ bacteria were cultured in each of eight flasks containing 1.0 L of

Sautons. Cultures were maintained at 37° C. in 7% CO₂ for 3 weeks. Supernatants were harvested by centrifugation and residual bacteria were removed by filtration (2 micron filters, Costar). The supernatant was concentrated 100 times on an Amicon filtration unit with a PM 10 filter. Concentrated *M. vaccae* culture supernatant was dialyzed against distilled H₂O and lyophilized.

Purification of the FN-Binding Protein

Concentrated *M. vaccae* culture supernatant was dialyzed against distilled H₂O and lyophilized. The lyophilized supernatant was reconstituted to 1.5 ml with 0.02M Bis-Tris, pH 6.0., and 0.7 ml was loaded onto an ACA 54 gel filtration column (0.6 cm×75 cm) equilibrated with 0.02M Bis-Tris. Inhibitory fractions were pooled and loaded onto 10 ml of DEAE-Sephacel. The column was washed with 0.02M Bis-Tris, pH 6.0 until the effluent was protein free. Protein was eluted with a 0-0.4M NaCl gradient in Bis-Tris. Fractions, 1.0 ml, were collected and dialyzed against Bis-Tris, pH 6.0. SDS-PAGE and Western blots were performed as described (Abou-Zeid et al., *Infect Immun.*, 56, 3046-3051 (1988)).

Antibodies

Polyclonal rabbit antibodies to the purified adhesin (p55) was prepared by injecting subcutaneously 25 µg in alum. At 3 week intervals the rabbit was boosted with 15-20 µg in alum. Ten to 14 days after the second boost antibody was harvested. IgG was isolated from serum by 50% ammonium sulfate precipitation followed by DEAE-Sephacel ion exchange chromatography. SDS-PAGE demonstrated only bands consistent with IgG heavy and light chains. All experiments using the polyclonal antibody were performed with DEAE purified antibody.

Monoclonal antibody to the p55 protein was generated by the subcutaneous injection of BALB/C mice with 10 µg p55 in alum. Mice were boosted three times at weekly intervals with 5 µg p55 in alum. Mice were rested 3-4 weeks after the third boost and injected IV with 5 µg p55 in PBS. Three days later spleens were harvested and fused with the NS1 myeloma. Reactive clones were detected by ELISA with purified p55-coated microtiter wells. A single hybridoma showed consistent reactivity in an ELISA assay. The reactive hybridoma was clones, and the antibody, designated mFNR.1, is typed as IgM λ .

p55 FN binding Assay

Immulon wells were coated with FN or BSA as a control for non-specific binding, as described above. The remaining attachment sites were blocked by the addition of 1% bovine serum albumin (BSA) in PBS for 30 minutes. Purified p55 in Tris buffer was added to appropriate wells (3 µg/well) and incubated for 30 min at room temperature. Wells were washed and purified mFNR.1 diluted in PBS containing 0.1% BSA was added for 1 hr at room temperature. The wells were washed and a biotinylated anti-mouse IJ (Sigma Chemicals, St. Louis, Mo.) was added at a predetermined optimal concentration for 1 hr. at room temperature. The wells were washed, and the reaction was developed by the addition of p-Nitrophenyl phosphate. Reactivity was read on an ELISA reader at a wave length of 405 nm. Controls included p55 added BSA-coated wells, FN-coated wells without p55, and FN-coated wells with a nonspecific primary isotype control (RL172.4; anti-thy 1.2). Control absorbance for all controls was equal to or less than that of the isotype control.

Results

Concentrated *M. vaccae* supernatant contains a component that inhibits FN binding to BCG. Purification of the inhibitory component(s) was initiated by applying supernatant to an ACA-54 gel filtration column previously equili-

brated with Bis-Tris, pH 6.0. The inhibitory activity was localized and pooled for further purification. SDS-PAGE on the pooled fractions revealed a primary protein band at 55 kDa (p55). The pooled ACA-54 inhibitory fractions were applied to a DEAE-Sephacel anion exchange column equilibrated with 0.02M Bis-Tris, pH 6.0. Bound protein was eluted with a 0–0.4M NaCl gradient in Bis-Tris, pH 6.0. The peak inhibitory activity eluted at 0.3M NaCl. SDA-PAGE on the 0.3M fraction revealed a single 55 kDa protein band. The protein from this fraction was used for all subsequent experiments and for immunization purposes. The protein purification scheme is summarized in Table 1. Amino acid sequencing by Edman degradation was unsuccessful, presumably because the amino terminus of p55 was blocked.

TABLE 1

Step	Purification of p55			Fold Purification
	Protein (mg/ml)	Volume	Total Protein	
Conc. Supernatant	11.16	0.7	7.8	—
ACA 54 Gel Filtration	0.07	8.0	0.57	13.7
DEAE-Sephacel (0–0.4 NaCl)	0.16	2.0	0.32	24.3

The purified p55 was tested for its ability to inhibit ¹²⁵I-FN binding to BCG; purified p55 inhibited FN attachment to BCG in a dose-dependent manner.

Purified p55 was used as an immunogen to generate a rabbit polyclonal and a mouse monoclonal antibody. The resulting polyclonal antibody blotted a single protein band at 55 kDa in crude *M. vaccae* supernatants. The single monoclonal antibody obtained was reactive by ELISA to purified p55 but was not effective in Western blots.

Further studies were performed to determine whether the purified p55 protein bound to FN. Microtiter wells were coated with FN as described above, after which purified p55 was added. The binding of p55 to FN was detected by either the polyclonal or monoclonal antibodies. The results, identical for both, demonstrate mFNR.1 binding to p55 treated FN coated surfaces increases as a function of the input of p55 suggesting a p55/FN interaction. Thus, p55 inhibits FN binding to BCG and binds directly to FN. Taken together the data show that the purified inhibitory component (p55) from the supernatant of *M. vaccae* is a FN binding protein.

Because this *M. vaccae* FN-binding protein had been purified based on its ability to inhibit FN binding to BCG, it was reasonable the BCG should contain a related protein. It was tested whether the polyclonal anti-p55 (made against *M. vaccae* FN-binding protein) recognized any BCG protein (s). To do this BCG were fractionated into cytosolic and cell wall components as described (Hunter et al., *J. Immunol.*, 142, 2864–2872 (1989)). The crude cell fractions were then subjected to Western blotting with the polyclonal anti-p55. An immunologically crossreactive protein at 55 kD was seen in the cell wall but not the cytosolic fraction from BCG. In addition, a protein at 100 kDa also faintly reacted with the antiserum. Thus, BCG expresses a protein(s) crossreactive with the *M. vaccae* FN binding protein in the cell wall.

It was tested whether mFNR.1, the mAb anti-p55, could inhibit the binding of intact, viable BCG to FN. mFNR.1 inhibited BCG binding to a FN-coated surface. Thus, an antigenically related protein is necessary for BCG binding to FN.

EXAMPLE 2

Cloning of FAP from *M. bovis* BCG (FAP-B)

M. bovis BCG DNA (3 μg) was digested with EcoRI, ligated into λZAP Express predigested vector (Stratagene,

La Jolla, Calif.) and packaged in vitro using the Gigapack II packaging extracts (Stratagene, La Jolla, Calif.). The use of the EcoRI restriction digest was predetermined by Southern blot. The EcoRI digest yielded a unique 3.5 kilobase (kbp) fragment when probed with a 400 basepair (bp) probe from the FAP-A coding region. The 400 bp probe was obtained by enzymatic digestion of the FAP-A coding region (depicted at Gen Bank accession No. MAU53585) with XbaI and PstI. The packaged DNA was titered and corresponded to 2.2×10⁶ plaque-forming units per ml. Greater than 90% of plaques contained BCG DNA. Approximately 5,000 plaques were transferred onto nitrocellulose filters (Schleicher & Schuell, Keene, N.H.) and screened with a 400 bp PCR product from the FAP-A coding region, which had been labeled with ³²P according to standard procedures (Schorey et al., *Infect. Immun.*, 63, 2652–2657 (1995)). The blot was hybridized using standard hybridization conditions as described above. The positive plaques were cloned. BCG DNA in these clones were removed from the λ arms using helper phage R408 and ligated into a pBK-CMV phagemid vector (Stratagene).

The isolated clones were digested with EcoRI and resolved on a 1% agarose gel. After DNA transfer to a nitrocellulose filter, the filter was hybridized with the 400 bp PCR fragment from the FAP-A coding region as described above. The positive clone contained the 3.5 kb FAP-B fragment. Digestion of the 3.5 kb insert with PstI yielded three fragments which were subcloned into pBluescript SK vector (Stratagene) to determine the nucleotide sequence. T3 and T7 plasmid primers were used in DNA sequencing. Two individual clones for each fragment were sequenced using the Taq DyeDeoxy Termination Cycle Kit and the Applied Biosystem 373A DNA sequencer (Applied Biosystems, Foster City, Calif.). The nucleotide sequence is shown in SEQ ID NO:1.

The complete FAP-B coding region is 978 nucleotides that encode a 325 amino acid protein with a signal sequence of 39 amino acids (FIG. 1). The predicted amino acid sequence of FAP-B shows similarity to FAP-A and FAP-L (61% and 71%, respectively; Schorey et al., *Mol. Microbiol.*, 21, 321–9 (1996), (Schorey et al., *Infect. Immun.*, 63, 2652–2657 (1995)). Comparison of the amino-terminal sequence of BCG 45/47kDa antigen with FAP-B and *M. tuberculosis* 45/47 kDa antigen indicates that FAP-B corresponds to the BCG 45/47 kDa antigen (Laqueyriere et al., *Infect. Immun.*, 63, 4003–10 (1995), Romain et al., *Infect. Immun.*, 61, 742–750 (1993)).

EXAMPLE 3

Expression and Purification of the FAP-B

The plasmid containing the 3.5 kb insert was digested with HpaI and EcoRI. The 2.3 kb HpaI-EcoRI fragment containing the FAP-B coding region was ligated into the expression vector pTrcHisB (Invitrogen, San Diego, Calif.), which had been digested with XhoI, blunt ended with Klenow and then digested with EcoRI. To delete the signal peptide and the subsequent 7 amino acids, the clone was digested with KpnI and EcoRI. The resulting 2.1 kb KpnI-EcoRI fragment was ligated into pTrcHisC (Invitrogen). The FAP-B fusion proteins contained a domain that included the poly-His tag and was fused to amino acid 47 of SEQ ID NO:2. The amino acid sequence of the domain was MGGSHHHHHHGMASMTGGQQMGRDLYD-DDKHRWIRPRDLQLV (SEQ ID NO:3). The FAP-B fusion proteins were expressed and purified using a N⁺⁺ affinity column under denaturing conditions according to the manufacturer's protocol (Invitrogen). The cell lysates and purified FAP-B were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and visu-

alized by Coomassie Blue staining. After electrophoresis, the antigens were also transferred to a nitrocellulose filter (Schleicher & Schuell), incubated with rabbit anti-FAP polyclonal antibodies (1:12000 dilution) and then incubated with mouse anti-rabbit IgG-HRP (1,4000 dilution, Sigma Chemical Co., St. Louis, Mo.). The bound HRP was detected with the ECL detection system (Amersham Life Science, Arlington Heights, Ill.).

The complete coding region of FAP-B encodes a protein with a predicted molecular mass of 35.3 kDa. When the full-length FAP-B was expressed in *E. coli* using the pTrcHisC vector, only low-level expression of FAP-B was obtained. A similarly low expression level of the full length FAP-A sequence was previously recorded (Ratliff et al., *Infect. Immun.*, 61,1889–1894 (1993)). As observed for FAP-A, increased expression was obtained by eliminating the signal sequence. The KpnI-EcoRI FAP-B DNA fragment FAP-B fusion protein does not contain a signal was ligated into the pTrcHisB vector. The resultant FAP-B fusion protein did not contain a signal peptide or the first 7 amino acids of the predicted mature FAP-B protein. The predicted molecular mass of the fusion protein was 35 kDa. Coomassie Blue staining showed this fusion protein migrated as a 50 kDa band on SDS-PAGE. This slow migration may result from its high proline content, which is consistent with previous observations for FAP-L and FAP-A (Laqueyrie et al., *Infect. Immun.*, 63, 4003–10 (1995); Ratliff et al., *J. Gen. Microbiol.*, 134, 1307–1313 (1988)). Western blot showed that rabbit anti-FAP-B polyclonal antibodies reacted with the 50 kDa FAP-B fusion protein as was previously observed for the FAP-A and FAP-L.

EXAMPLE 4

Attachment of FAP to Fibronectin

Ninety-six-well Immulon II plates (Dynatech, Chantilly, Va.) were coated with 1 μ g of human fibronectin (Collaborative Biomedical Products, Bedford, Mass.) or bovine serum albumin (BSA) at 37° C. overnight. Recombinant FAP-B, FAP-A, and β -galactosidase fusion proteins were produced in the pTrcHis vector and purified as described for FAP-B, were biotinylated with NHS-LC-Biotin (Pierce, Rockford, Ill.). Biotinylated FAP-B, FAP-A and β -galactosidase fusion proteins (0.5 μ g and 2 μ g) were added to wells coated with fibronectin or BSA and incubated at 25° C. for 1 hour. The bound fusion proteins were detected with streptavidin-HRP (1:10,000 dilution; Pierce) and o-phenylenediamine dihydrochloride (Sigma) substrate.

For the fibronectin binding inhibition assay, the plates were coated with 1 μ g human fibronectin (Collaborative Biomedical Products, Bedford, Mass.) or BSA. After the plates were incubated with anti-human fibronectin antibodies (1:100 dilution goat anti-fibronectin), anti-FAP-V antibodies (1:100 dilution), or 6 μ g FAP-A peptides at 25° C. for 1 hour, biotinylated FAP-B (or FAP-B preincubated with rabbit anti-FAP antibody) was added into each well. The bound biotinylated FAP-B fusion protein was detected with streptavidin-HRP and o-phenylenediamine dihydrochloride substrate. Absorbance was measured at 420 nm.

Both purified recombinant FAP-B and FAP-A bound to wells coated with fibronectin. In contrast the control recombinant fusion protein, β -galactosidase, did not bind to fibronectin (FIG. 2). Binding of FAP-B to fibronectin was inhibited by either antibodies to fibronectin or antibodies to FAP-V as previously reported for FAP-L and FAP-A (Ratliff et al., *Infect. Immun.*, 61, 1889–1894 (1993); Schorey et al., *Mol. Microbiol.*, 21, 321–9 (1996); FIG. 3A),

Previous studies with FAP-L and FAP-A identified two highly conserved fibronectin binding regions (Ratliff et al.,

Infect. Immun., 61, 1889–1894 (1993)). One of the regions (amino acids 269–292 in FAP-A and its homologue in FAP-L, amino acids 240–263) was shown to be sufficient to block the attachment of BCG to fibronectin coated surfaces and also BCG attachment to epithelial cells. Since FAP-B also was observed to contain the highly conserved region, the ability of FAP-A₂₆₉₋₂₉₂ to inhibit the attachment of FAP-B to fibronectin was tested as described (Ratliff et al., *Infect. Immun.*, 61, 1889–1894 (1993)). FAP-A₂₆₉₋₂₉₂ and a control peptide consisting of identical amino acids in a randomly ordered sequence were incubated with fibronectin coated well for 30 minutes at room temperature prior to the addition of biotinylated FAP-B. FAP-A₂₆₉₋₂₉₂ completely blocked the binding of FAP-B to fibronectin, whereas the corresponding scrambled peptide did not affect binding (FIG. 3B). These data show that FAP-B functions as a fibronectin attachment protein and suggest that the highly conserved binding regions of each FAP are necessary for fibronectin binding.

EXAMPLE 5

FAP-mediated Inhibition of BCG Attachment to Fibronectin

BCG attachment was performed as previously described (Ratliff et al., *Infect. Immun.*, 61, 1889–1894 (1993)). Briefly, Immulon 96 well microtiter plates were coated overnight at 25° C. with 3 μ g/ml fibronectin or BSA. After blocking non-specific sites with BSA, a total of 2×10^6 colony forming units (CFU) of fluorescein isothiocyanate (FITC)-labeled BCG were added in a volume of 50 μ l PBS-0.1% BSA. In blocking experiments recombinant FAP-A or FAP-B (1 μ M) or inhibitory peptides were added in a volume of 50 μ l PBS-0.1% BSA before the addition of BCG. The inhibitory peptides were 1.0 μ M control J, which is recombinant thioredoxin produced and purified as described for FAP-A and FAP-B proteins, and 6 μ g/ml control peptide. After 90 minutes incubation at 37° C., the wells were washed with PBS and bound FITC-labeled BCG were detected using a Cytofluor 2300 Series System (Millipore, Bedford, Mass.). The ability of FAP-B to inhibit BCG attachment to fibronectin is shown in FIG. 4. These data show that FAP-B, FAP-A, and FAP-A₂₆₉₋₂₉₂ inhibit BCG attachment to fibronectin in an equivalent manner. These data suggest functional equivalence among FAP proteins.

EXAMPLE 6

Prevention of Airway Eosinophilia and Bronchial Hyperactivity

A murine model of asthma was used to test whether an immune response to the FAP-B protein could induce protection against Th-2 mediated responses such as asthma.

Murine Model of Immunotherapy for Asthma

The timing of injections and challenges is depicted in FIG. 5. Female C57BL/6 mice (6–8 week old, Jackson Laboratories) were sensitized to ovalbumin (10 μ g, precipitated in alum, in 100 μ l PBS) by intraperitoneal injection on days 0 and 7, and subsequently challenged with ovalbumin (6% solution in HBSS) by inhalation (30 minutes daily) on days 14–18. Challenges with ovalbumin were administered by nebulization. Some mice also received FAP-B by intraperitoneal injection prior to sensitization (100 μ g, days -1, 0, 6, 7, 14). FAP-B was cloned, expressed, and isolated as described herein. Other (control) mice received FAP-B injections (on the same schedule) without exposure to ovalbumin. Three groups of mice thus received: 1) ovalbumin alone (OVA); 2) FAP-B alone (FAP-B); and 3) both ovalbumin and FAP-B (FAP-B/OVA). All mice underwent assessment of airway reactivity to inhaled methacholine at baseline (Day -1) and prior to sacrifice (Day 19). All mice were sacrificed 24 hours after the final exposure to ovalbumin.

Lung Lavage

At the time of sacrifice, mice were subjected to whole lung lavage (BAL) to measure cell infiltration. Three milliliters of PBS were administered through a tracheostomy cannula at a pressure of 7-cm H₂O, and recovered by gravity flow. Cytospin slide preparations were produced using 15 microliters of BAL, stained using DiffQuik, and total and differential cell counts were performed. Mice that received FAP-B immediately prior to sensitization to ovalbumin developed significantly less BAL eosinophilia than the mice which received ovalbumin, in the absence of any FAP-B, and mice that received FAP-B alone exhibited almost no lung eosinophilia (*p<0.01 vs OVA) (FIG. 6A). Both the FAP-B/OVA mice and the OVA mice developed significant neutrophilia relative to the FAP-B mice (‡p<0.01 vs FAP-B, *p<0.01 vs OVA) (FIG. 6B).

Physiology

Airway hyperreactivity was assessed by methacholine-induced airflow obstruction. Mice were evaluated using a whole body plethysmograph (Buxco, Sharon, Conn.) at the start of the study as well as immediately prior to sacrifice. Measurement was made of respiratory rate, tidal volume, and enhanced pause. Airway resistance is expressed as: $P_{enh} = [(T_e/0.3 T_r) - 1] \times [2 P_{ef}/3 P_{if}]$, where P_{enh} =enhanced pause, T_e =expiratory time (seconds), T_r =relaxation time (seconds), P_{ef} =peak expiratory flow (ml/sec), and P_{if} =peak inspiratory flow (ml/sec). Increasing doses of methacholine (0–100 mg/ml) were administered by nebulization, and P_{enh} was calculated over the subsequent 3 minutes.

At baseline, no significant difference in methacholine responsiveness was detected between the groups (FIG. 7A); following the ovalbumin inhalational challenge, however, the FAP-B/OVA mice were significantly less reactive than OVA mice (FIG. 7B, *p<0.05, vs OVA). There were no differences in responsiveness to inhaled methacholine between the two timepoints in the FAP-B (FIG. 7C) or FAP-B/OVA mice (FIG. 7D), but, following the ovalbumin inhalation, there was a significant increase in P_{enh} response to the higher doses of methacholine in the OVA mice (FIG. 3E).

Splenocyte Culture

In a separate series of experiments, C57BL/6 mice (four/group) were injected with saline (Control), FAP-B (100 µg), ovalbumin (10 µg in alum, OVA), or ovalbumin and FAP-B

(FAP-B/OVA) weekly for three weeks. Subsequently, the mice were sacrificed, their spleens were removed en bloc, and splenocytes isolated. Splenocytes were cultured at 2×10^6 cells/ml in RPMI-1640 with 10% FCS, 10 mM HEPES, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were cultured for 24–72 hours in unstimulated conditions or after the addition of ovalbumin (40 µg ovalbumin/100 µl well). Supernatants were harvested at 48 hours, immediately frozen at -70° C., and subsequently batch processed to detect cytokines.

Murine IL-4, IL-12, and IFN-γ were measured using a sandwich ELISA (R&D, Minneapolis, Minn.) according to the manufacturer's instructions. The IL-12 ELISA uses a capture antibody specific to the p70 heterodimer (R&D Systems, Minneapolis, Minn.). Unstimulated splenocytes released no detectable IL-12. Regarding the OVA-stimulated-cells, splenocytes harvested from the FAP-B/OVA group of mice released significantly more IL-12 than the cells from the control, FAP-B, and OVA groups (*p<0.05 vs OVA, <0.01 vs control, FAP-B). There was no detectable differences in release of IL-4 or of IFN-γ.

These data show that FAP-B is an effective immunomodulator in a murine model of atopic asthma, that FAP-B reduces airway eosinophilia as well as bronchial hyperresponsiveness to inhaled methacholine, and that the effects of FAP-B are associated with an induction of antigen-specific release of IL-12. These data also suggest that the immune response to FAP-B may be responsible for the delayed hypersensitivity to mycobacterial antigens.

The complete disclosure of all patents, patent applications, and publications, and electronically available material (e.g., GenBank amino acid and nucleotide sequence submissions) cited herein are incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

Sequence Listing Free Text

SEQ ID NO:1 Nucleotide sequence of FAP-B
 SEQ ID NO:2 Amino acid sequence of FAP-B
 SEQ ID NO:3 Vector-encoded amino terminal domain

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 1122

<212> TYPE: DNA

<213> ORGANISM: Mycobacterium bovis

<400> SEQUENCE: 1

```

caccaccacac acacgccagt tcacgagccg acccgcgccg tctctgcgtc gcgccgtaa      60
cacgagaggtt cttcgccatg catcagggtg accccaactt gacacgtcgc aagggacgat      120
tgggggcact ggctatcgcg gcgatggcca gcgccagcct ggtgaccgtt gcggtgcccg      180
cgaccgccaa cgccgatccg gagccagcgc ccccggtacc cacaacggcc gcctcgccgc      240
cgtcgaccgc tgcagcgcca cccgcaccgg cgacacctgt tgcccccca ccaccggccg      300
ccgccaacac gccgaatgcc cagccggggc atcccaacgc agcaccctcg ccggccgacc      360

```

-continued

```

cgaacgcacc gccgccacct gtcattgccc caaacgcacc ccaacctgtc cggatcgaca 420
accgggttgg aggattcagc ttcgcgctgc ctgctggctg ggtggagtct gacgccgccc 480
acctcgacta cggttcagca ctctcagca aaaccaccgg ggaccgcga tttcccggac 540
agccgccgcc ggtggccaat gacaccgta tcgtgctcgg ccggctagac caaaagcttt 600
acgccagcgc cgaagccacc gactccaagg ccgcggcccg gttgggctcg gacatgggtg 660
agttctatat gccctaccgg ggcaccgga tcaaccagga aaccgtctcg ctcgacgcca 720
acggggtgtc tgaagcgcg tcgtattacg aagtaagtt cagcgatccg agtaagccga 780
acggccagat ctggacgggc gtaatcggct cgcccgcggc gaacgcaccg gacgccgggc 840
cccctcagcg ctggtttgtg gtatggctcg ggaccgcaa caaccgggtg gacaagggcg 900
cggccaaggc gctggccgaa tcgatccgpc ctttggtcgc cccgccgccc gcgccggcac 960
cggctcctgc agagcccgc cggcgcccgg cgccggcccg ggaagtcgct cctaccccga 1020
cgacaccgac accgcagcgg accttaccgg cctgaccgga tccggccgca cccaagtga 1080
taccctgggg cggggtgtca gcgcggcccg gcgctcttga gc 1122
    
```

```

<210> SEQ ID NO 2
<211> LENGTH: 325
<212> TYPE: PRT
<213> ORGANISM: Mycobacterium bovis
    
```

<400> SEQUENCE: 2

```

Met His Gln Val Asp Pro Asn Leu Thr Arg Arg Lys Gly Arg Leu Ala
1 5 10 15
Ala Leu Ala Ile Ala Ala Met Ala Ser Ala Ser Leu Val Thr Val Ala
20 25 30
Val Pro Ala Thr Ala Asn Ala Asp Pro Glu Pro Ala Pro Val Pro
35 40 45
Thr Thr Ala Ala Ser Pro Pro Ser Thr Ala Ala Ala Pro Pro Ala Pro
50 55 60
Ala Thr Pro Val Ala Pro Pro Pro Ala Ala Ala Asn Thr Pro Asn
65 70 75 80
Ala Gln Pro Gly Asp Pro Asn Ala Ala Pro Pro Ala Asp Pro Asn
85 90 95
Ala Pro Pro Pro Pro Val Ile Ala Pro Asn Ala Pro Gln Pro Val Arg
100 105 110
Ile Asp Asn Pro Val Gly Gly Phe Ser Phe Ala Leu Pro Ala Gly Trp
115 120 125
Val Glu Ser Asp Ala Ala His Leu Asp Tyr Gly Ser Ala Leu Leu Ser
130 135 140
Lys Thr Thr Gly Asp Pro Pro Phe Pro Gly Gln Pro Pro Pro Val Ala
145 150 155 160
Asn Asp Thr Arg Ile Val Leu Gly Arg Leu Asp Gln Lys Leu Tyr Ala
165 170 175
Ser Ala Glu Ala Thr Asp Ser Lys Ala Ala Ala Arg Leu Gly Ser Asp
180 185 190
Met Gly Glu Phe Tyr Met Pro Tyr Pro Gly Thr Arg Ile Asn Gln Glu
195 200 205
Thr Val Ser Leu Asp Ala Asn Gly Val Ser Gly Ser Ala Ser Tyr Tyr
210 215 220
Glu Val Lys Phe Ser Asp Pro Ser Lys Pro Asn Gly Gln Ile Trp Thr
225 230 235 240
    
```

-continued

Gly Val Ile Gly Ser Pro Ala Ala Asn Ala Pro Asp Ala Gly Pro Pro
 245 250 255

Gln Arg Trp Phe Val Val Trp Leu Gly Thr Ala Asn Asn Pro Val Asp
 260 265 270

Lys Gly Ala Ala Lys Ala Leu Ala Glu Ser Ile Arg Pro Leu Val Ala
 275 280 285

Pro Pro Pro Ala Pro Ala Pro Ala Pro Ala Glu Pro Ala Pro Ala Pro
 290 295 300

Ala Pro Ala Gly Glu Val Ala Pro Thr Pro Thr Thr Pro Thr Pro Gln
 305 310 315 320

Arg Thr Leu Pro Ala
 325

<210> SEQ ID NO 3
 <211> LENGTH: 42
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: VECTOR-ENCODED AMINO TERMINAL DOMAIN

<400> SEQUENCE: 3

Met Gly Gly Ser His His His His His His Gly Met Ala Ser Met Thr
 1 5 10 15

Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Lys His Arg
 20 25 30

Trp Ile Arg Pro Arg Asp Leu Gln Leu Val
 35 40

<210> SEQ ID NO 4
 <211> LENGTH: 287
 <212> TYPE: PRT
 <213> ORGANISM: Mycobacterium leprae

<400> SEQUENCE: 4

Met Asn Gln Val Asp Leu Asp Ser Thr His Arg Lys Gly Leu Trp Ala
 1 5 10 15

Ile Leu Ala Ile Ala Val Val Ala Ser Ala Ser Ala Phe Thr Met Pro
 20 25 30

Leu Pro Ala Ala Ala Asn Ala Asp Pro Ala Pro Leu Pro Pro Ser Thr
 35 40 45

Ala Thr Ala Ala Pro Ser Pro Ala Gln Glu Ile Ile Thr Pro Leu Pro
 50 55 60

Gly Ala Pro Val Ser Ser Glu Ala Gln Pro Gly Asp Pro Asn Ala Pro
 65 70 75 80

Ser Leu Asp Pro Asn Ala Pro Tyr Pro Leu Ala Val Asp Pro Asn Ala
 85 90 95

Gly Arg Ile Thr Asn Ala Val Gly Gly Phe Ser Phe Val Leu Pro Ala
 100 105 110

Gly Trp Val Glu Ser Glu Ala Ser His Leu Asp Tyr Gly Ser Val Leu
 115 120 125

Leu Ser Lys Ala Ile Glu Gln Pro Pro Val Leu Gly Gln Pro Thr Val
 130 135 140

Val Ala Thr Asp Thr Arg Ile Val Leu Gly Arg Leu Asp Gln Lys Leu
 145 150 155 160

Tyr Ala Ser Ala Glu Ala Asp Asn Ile Lys Ala Ala Val Arg Leu Gly
 165 170 175

-continued

Ser Asp Met Gly Glu Phe Tyr Leu Pro Tyr Pro Gly Thr Arg Ile Asn
180 185 190

Gln Glu Thr Ile Pro Leu His Ala Asn Gly Ile Ala Gly Ser Ala Ser
195 200 205

Tyr Tyr Glu Val Lys Phe Ser Asp Pro Asn Lys Pro Ile Gly Gln Ile
210 215 220

Cys Thr Ser Val Val Gly Ser Pro Ala Ala Ser Thr Pro Asp Val Gly
225 230 235 240

Pro Ser Gln Arg Trp Phe Val Val Trp Leu Gly Thr Ser Asn Asn Pro
245 250 255

Val Asp Lys Gly Ala Ala Lys Glu Leu Ala Glu Ser Ile Arg Ser Glu
260 265 270

Met Ala Pro Ile Pro Ala Ser Val Ser Ala Pro Ala Pro Val Gly
275 280 285

<210> SEQ ID NO 5
<211> LENGTH: 381
<212> TYPE: PRT
<213> ORGANISM: Mycobacterium avium

<400> SEQUENCE: 5

Met Asp Gln Val Glu Ala Thr Ser Thr Arg Arg Lys Gly Leu Trp Thr
1 5 10 15

Thr Leu Ala Ile Thr Thr Val Ser Gly Ala Ser Ala Val Val Ile Ala
20 25 30

Leu Pro Glu Thr Ser His Ala Asp Pro Glu Val Pro Thr Pro Val Pro
35 40 45

Pro Ser Thr Ala Thr Thr Pro His Pro Arg Arg Arg Arg Ile Pro Gly
50 55 60

Gln Pro Ala Asp Asn Ala Gln Ala Gly Ala Pro Ala Pro Ala Pro Asn
65 70 75 80

Gly Gln Gln Arg Pro Pro Arg Arg Arg Arg Met Ile Pro Thr Arg Ala
85 90 95

Pro Pro Pro Ala Gly Ala Pro Pro Asn Gly Ala Pro Pro Ala Ala Pro
100 105 110

Asn Gly Ala Pro Pro Pro Pro Val Asp Pro Asn Ala Pro Pro Pro Pro
115 120 125

Pro Ala Asp Pro Asn Ala Gly Arg Ile Pro Asn Ser Tyr Val Leu Pro
130 135 140

Ala Gly Trp Val Glu Ser Asp Ala Ser His Leu Asp Tyr Gly Ser Ala
145 150 155 160

Leu Leu Ser Lys Val Thr Gly Pro Pro Pro Met Pro Asp Gln Pro Pro
165 170 175

Pro Val Ala Asn Asp Thr Arg Ile Val Met Gly Arg Val Asp Gln Lys
180 185 190

Leu Tyr Ala Ser Ala Glu Ala Asn Asn Ala Lys Ala Ala Val Gly Leu
195 200 205

Gly Ser Asp Met Gly Glu Phe Phe Met Pro Tyr Pro Gly Thr Arg Ile
210 215 220

Asn Gln Asp Ser Thr Pro Leu Asn Gly Ala Asn Gly Ser Thr Gly Ser
225 230 235 240

Ala Ser Tyr Tyr Glu Val Lys Phe Ser Asp Ala Ser Lys Pro Asn Gly
245 250 255

Gln Ile Trp Thr Gly Val Ile Gly Ser Ala Asn Ala Gly Asn Arg Gln
260 265 270

-continued

Arg Trp Phe Val Val Trp Leu Gly Thr Ser Asn Asp Pro Val Asp Lys
 275 280 285

Val Ala Ala Lys Ala Leu Ala Glu Ser Ile Gln Ala Trp Thr Pro Pro
 290 295 300

Pro Ala Pro Pro Ala Ala Pro Gly Gly Pro Gly Ala Pro Ala Pro Gly
 305 310 315 320

Ala Pro Gly Ala Pro Ala Pro Gly Ala Pro Ala Ala Pro Gly Val Thr
 325 330 335

Ala Pro Ala Ala Pro Ala Pro Ala Ala Pro Gly Ala Pro Ala Ala Pro
 340 345 350

Gly Ala Pro Ala Pro Glu Pro Gly Gln Ala Pro Ala Val Glu Val Ser
 355 360 365

Pro Thr Pro Thr Pro Thr Pro Gln Gln Thr Leu Ser Ala
 370 375 380

<210> SEQ ID NO 6
 <211> LENGTH: 325
 <212> TYPE: PRT
 <213> ORGANISM: Mycobacterium tuberculosis

<400> SEQUENCE: 6

Met His Gln Val Asp Pro Asn Leu Thr Arg Arg Lys Gly Arg Leu Ala
 1 5 10 15

Ala Leu Ala Ile Ala Ala Met Ala Ser Ala Ser Leu Val Thr Val Ala
 20 25 30

Val Pro Ala Thr Ala Asn Ala Asp Pro Glu Pro Ala Pro Pro Val Pro
 35 40 45

Thr Thr Ala Ala Ser Pro Pro Ser Thr Ala Ala Ala Pro Pro Ala Pro
 50 55 60

Ala Thr Pro Val Ala Pro Pro Pro Pro Ala Ala Ala Asn Thr Pro Asn
 65 70 75 80

Ala Gln Pro Gly Asp Pro Asn Ala Ala Pro Pro Pro Ala Asp Pro Asn
 85 90 95

Ala Pro Pro Pro Pro Val Ile Ala Pro Asn Ala Pro Gln Pro Val Arg
 100 105 110

Ile Asp Asn Pro Val Gly Gly Phe Ser Phe Ala Leu Pro Ala Gly Trp
 115 120 125

Val Glu Ser Asp Ala Ala His Phe Asp Tyr Gly Ser Ala Leu Leu Ser
 130 135 140

Lys Thr Thr Gly Asp Pro Pro Phe Pro Gly Gln Pro Pro Pro Val Ala
 145 150 155 160

Asn Asp Thr Arg Ile Val Leu Gly Arg Leu Asp Gln Lys Leu Tyr Ala
 165 170 175

Ser Ala Glu Ala Thr Asp Ser Lys Ala Ala Ala Arg Leu Gly Ser Asp
 180 185 190

Met Gly Glu Phe Tyr Met Pro Tyr Pro Gly Thr Arg Ile Asn Gln Glu
 195 200 205

Thr Val Ser Leu Asp Ala Asn Gly Val Ser Gly Ser Ala Ser Tyr Tyr
 210 215 220

Glu Val Lys Phe Ser Asp Pro Ser Lys Pro Asn Gly Gln Ile Trp Thr
 225 230 235 240

Gly Val Ile Gly Ser Pro Ala Ala Asn Ala Pro Asp Ala Gly Pro Pro
 245 250 255

Gln Arg Trp Phe Val Val Trp Leu Gly Thr Ala Asn Asn Pro Val Asp
 260 265 270

-continued

Lys Gly Ala Ala Lys Ala Leu Ala Glu Ser Ile Arg Pro Leu Val Ala
 275 280 285

Pro Pro Pro Ala Pro Ala Pro Ala Pro Ala Glu Pro Ala Pro Ala Pro
 290 295 300

Ala Pro Ala Gly Glu Val Ala Pro Thr Pro Thr Thr Pro Thr Pro Gln
 305 310 315 320

Arg Thr Leu Pro Ala
 325

<210> SEQ ID NO 7
 <211> LENGTH: 286
 <212> TYPE: PRT
 <213> ORGANISM: Mycobacterium tuberculosis

<400> SEQUENCE: 7

Asp Pro Glu Pro Ala Pro Pro Val Pro Thr Thr Ala Ala Ser Pro Pro
 1 5 10 15

Ser Thr Ala Ala Ala Pro Pro Ala Pro Ala Thr Pro Val Ala Pro Pro
 20 25 30

Pro Pro Ala Ala Ala Asn Thr Pro Asn Ala Gln Pro Gly Asp Pro Asn
 35 40 45

Ala Ala Pro Pro Pro Ala Asp Pro Asn Ala Pro Pro Pro Pro Val Ile
 50 55 60

Ala Pro Asn Ala Pro Gln Pro Val Arg Ile Asp Asn Pro Val Gly Gly
 65 70 75 80

Phe Ser Phe Ala Leu Pro Ala Gly Trp Val Glu Ser Asp Ala Ala His
 85 90 95

Phe Asp Tyr Gly Ser Ala Leu Leu Ala Lys Thr Thr Gly Asp Pro Pro
 100 105 110

Phe Pro Gly Gln Pro Pro Pro Val Ala Asn Asp Thr Arg Ile Val Leu
 115 120 125

Gly Arg Leu Asp Gln Lys Leu Tyr Ala Ser Ala Glu Ala Thr Asp Ser
 130 135 140

Lys Ala Ala Ala Arg Leu Gly Ser Asp Met Gly Glu Phe Tyr Met Pro
 145 150 155 160

Tyr Pro Gly Thr Arg Ile Asn Gln Glu Thr Val Ser Leu Asp Ala Asn
 165 170 175

Gly Val Ser Gly Ser Ala Ser Tyr Tyr Glu Val Lys Phe Ser Asp Pro
 180 185 190

Ser Lys Pro Asn Gly Gln Ile Trp Thr Gly Val Ile Gly Ser Pro Ala
 195 200 205

Ala Asn Ala Pro Asp Ala Gly Pro Pro Gln Arg Trp Phe Val Val Trp
 210 215 220

Leu Gly Thr Ala Asn Asn Pro Val Asp Lys Gly Ala Ala Lys Ala Leu
 225 230 235 240

Ala Glu Ser Ile Arg Pro Leu Val Ala Pro Pro Pro Ala Pro Ala Pro
 245 250 255

Ala Pro Ala Glu Pro Ala Pro Ala Pro Ala Pro Ala Gly Glu Val Ala
 260 265 270

Pro Thr Pro Thr Thr Pro Thr Pro Gln Arg Thr Leu Pro Ala
 275 280 285

<210> SEQ ID NO 8
 <211> LENGTH: 287
 <212> TYPE: PRT
 <213> ORGANISM: Mycobacterium leprae

-continued

<400> SEQUENCE: 8

```

Met Asn Gln Val Asp Leu Asp Ser Thr His Arg Lys Gly Leu Trp Ala
1          5          10          15
Ile Leu Ala Ile Ala Val Val Ala Ser Ala Ser Ala Phe Thr Met Pro
          20          25          30
Phe Arg Ala Ala Ala Asn Ala Asp Pro Ala Pro Leu Pro Pro Ser Thr
          35          40          45
Ala Thr Ala Ala Pro Ser Pro Ala Gln Glu Ile Ile Thr Pro Leu Pro
          50          55          60
Gly Ala Pro Val Ser Ser Glu Ala Gln Pro Gly Asp Pro Asn Ala Pro
65          70          75          80
Ser Leu Asp Pro Asn Ala Pro Tyr Pro Leu Ala Val Asp Pro Asn Ala
          85          90          95
Gly Arg Ile Thr Asn Ala Val Gly Gly Phe Ser Phe Val Leu Pro Ala
          100          105          110
Gly Trp Val Glu Ser Glu Ala Ser His Leu Asp Tyr Gly Ser Val Leu
          115          120          125
Leu Ser Lys Ala Ile Glu Gln Pro Pro Val Leu Gly Gln Pro Thr Val
          130          135          140
Val Ala Thr Asp Thr Arg Ile Val Leu Gly Arg Leu Asp Gln Lys Leu
145          150          155          160
Tyr Ala Ser Ala Glu Ala Asp Asn Ile Lys Ala Ala Val Arg Leu Gly
          165          170          175
Ser Asp Met Gly Glu Phe Tyr Leu Pro Tyr Pro Gly Thr Arg Ile Asn
          180          185          190
Gln Glu Thr Ile Pro Leu His Ala Asn Gly Ile Ala Gly Ser Ala Ser
          195          200          205
Tyr Tyr Glu Val Lys Phe Ser Asp Pro Asn Lys Pro Ile Gly Gln Ile
210          215          220
Cys Thr Ser Val Val Gly Ser Pro Ala Ala Ser Thr Pro Asp Val Gly
225          230          235          240
Pro Ser Gln Arg Trp Phe Val Val Trp Leu Gly Thr Ser Asn Asn Pro
          245          250          255
Val Asp Lys Gly Ala Ala Lys Glu Leu Ala Glu Ser Ile Arg Ser Glu
          260          265          270
Met Ala Pro Ile Pro Ala Ser Val Ser Ala Pro Ala Pro Val Gly
          275          280          285

```

What is claimed is:

1. A method for treating at least one symptom of an inflammatory response in a mammal comprising:

administering an effective amount of an isolated microbial polypeptide to the mammal such that at least one symptom of the inflammatory response is inhibited, wherein the microbial polypeptide comprises an amino acid sequence of SEQ ID NO:2, and wherein the at least one symptom is associated with asthma.

2. A method for treating at least one symptom of an inflammatory response in a mammal comprising administering to the mammal an isolated polypeptide such that at least one symptom of the inflammatory response is inhibited, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:3 and amino acids 47 to 325 of SEQ ID NO:2, wherein the carboxy terminal amino acid of SEQ ID NO:3 is fused to the amino terminal amino acid of amino acids 47 to 325 of SEQ ID NO:2, and wherein the at least one symptom is associated with asthma.

3. A method for treating at least one symptom of an inflammatory response in a mammal comprising:

administering an effective amount of an isolated microbial polypeptide to the mammal such that at least one symptom of the inflammatory response is inhibited, wherein the microbial polypeptide comprises amino acids 121 to 283 of SEQ ID NO:2, and wherein the at least one symptom is associated with asthma.

4. The method of claim 3 wherein the amino acid sequence of the microbial polypeptide comprises amino acids 112 to 283 of SEQ ID NO:2.

5. The method of claim 3 wherein the amino acid sequence of the microbial polypeptide comprises amino acids 47 to 325 of SEQ ID NO:2.

6. The method of claim 3 wherein the microbial polypeptide comprises an amino acid sequence of SEQ ID NO:3 and amino acids 47 to 325 of SEQ ID NO:2, wherein the carboxy

35

terminal amino acid of SEQ ID NO:3 is fused to the amino terminal amino acid of amino acids 47 to 325 of SEQ ID NO:2.

7. The method of claim 1 wherein the microbial polypeptide decreases lung eosinophila in the mammal.

8. The method of claim 1 wherein the microbial polypeptide decreases airway hyperactivity in the mammal.

9. The method of claim 2 wherein the polypeptide decreases lung eosinophila in the mammal.

36

10. The method of claim 2 wherein the polypeptide decreases airway hyperactivity in the mammal.

11. The method of claim 3 wherein the microbial polypeptide decreases lung eosinophila in the mammal.

12. The method of claim 3 wherein the microbial polypeptide decreases airway hyperactivity in the mammal.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,638,518 B1
DATED : October 28, 2003
INVENTOR(S) : Ratliff et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.

Item [56], **References Cited**, OTHER PUBLICATIONS, please insert -- Del Prete et al., "IL-4 is an Essential Factor for the IgE Synthesis Induced in vitro by Human T Cell Clones and Their Supernatants," *J. Immunol.*, 140(12):4193-4198 (1988). --.

Evans et al. reference, delete "1965-184" and insert -- 1965-1984 --.

Romain et al. reference, delete "Kitodalton" and insert -- Kilodalton --.

Column 2.

Line 50, delete "≠" and insert -- - --.

Column 8.

Line 59, delete "parenternal" and insert -- parenteral --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,638,518 B1
DATED : October 28, 2003
INVENTOR(S) : Ratliff et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 11,

Line 49, insert the following paragraph:

--Alternatively, individual organisms, preferably microbes, can be screened for the presence of polypeptides that are capable of inhibiting at least one symptom of an inflammatory response in a mammal. Typically, polypeptides are isolated from an organism and evaluated using the animal model described in Example 6. Once a polypeptide is identified that decreases eosinophilia or decreases responsiveness to inhaled methacholine, the polypeptide can be used in the methods of the present invention, or the polynucleotide sequence encoding the polypeptide can be isolated using methods detailed herein. Organisms, preferably microbes, can also be screened for the presence of polypeptides useful in the present invention by using antibodies prepared against a polypeptide having the amino acid sequence of SEQ ID NO:2, or prepared against a polypeptide having the amino acid sequence depicted at GenBank accession Nos. AAB34676, AAB50543, AAB71842, CAA56555, AAB36458, or P46842. Rabbit polyclonal antibodies against *M. vaccae* FAP (FAP-V) have been prepared that reacted with FAP-B, FAP-A, and FAP-L proteins on Western blots. A monoclonal antibody that can be used is described in U.S. Patent 5,618,916 (Ratliff et al.).--.

Signed and Sealed this

Seventeenth Day of February, 2004



JON W. DUDAS
Acting Director of the United States Patent and Trademark Office